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Abstract 
The aim of the work described in this thesis was to investigate the value of 
conventional, perfusion- and diffusion-weighted magnetic resonance imaging (MRI) 
in patients with histology-proven low-grade gliomas (LGG), and the potential role of 
these methods in the management of patients with these brain tumours. 
Thirty-six patients were studied at the National Hospital for Neurology and 
Neurosurgery using conventional, perfusion-weighted and diffusion-weighted MRI 
at study entry and 6 monthly intervals thereafter. At each visit, tumour volume, 
maximum rCBV and ADC histogram measures were calculated. This is a unique 
cohort, as patients were treatment free until malignant transformation was diagnosed, 
which translates the natural history of these brain tumours. It is unlikely to find such 
a specific cohort as most of the patients receive treatment after the initial diagnosis 
of low grade gliomas. 
Chapters 1 and 2 of this thesis describe the theoretical basis of the MRI techniques 
used, and summarise the natural history and imaging aspects of cerebral gliomas. 
Chapter 3 describes a methodological study relating to tumour perfusion 
measurement: since the inclusion or exclusion of intratumoural vessels may 
influence the quantification of relative cerebral blood volume (rCBV), a study was 
conducted to choose the best ROI placement technique to be used for the rCBV 
measurements included in this thesis. It was shown that only the approach which 
excluded intratumoural vessels demonstrated a significant association between rCBV 
values and tumour subtypes (astrocytomas, oligodendrogliomas and 
oligoastrocytomas) and therefore this technique was used in all subsequent rCBV 
measurements.  
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In chapter 4, it was investigated whether rCBV is a useful outcome predictor in 
patients with low-grade gliomas. We found that in LGG susceptibility-weighted MR 
perfusion imaging not only allows differentiation between histological tumour 
subtypes but also between two different outcome groups. More importantly, rCBV at 
study entry can be used to predict time to transformation in these patients. 
To complement these studies we assessed the utility of rCBV in predicting clinical 
response in 2 patient groups with low-grade glioma, studied at two separate 
institutions. The results presented in chapter 5 suggested that glioma rCBV correlates 
with time to progression or death, independently of institution, despite different 
approaches to patient management at the two sites.  
Finally, in chapter 6 we analyzed which quantitative MRI measure (tumour volume, 
rCBV and ADC) was the best predictor of outcome (stable, progressive disease or 
death). We found that tumour volume at study entry, at 6 and at 12 months, and its 
short-term changes were stronger predictors of outcome in patients with low-grade 
glioma than, and independent of, rCBV, diffusion histogram parameters, age, gender, 
histology and treatment.  Moreover tumour growth was the best predictor of time to 
transformation and tumour volume was the only independent predictor of time to 
death. Since this parameter can readily be obtained in any MRI centre and be 
quantified with an automated method, it may become a useful prognostic factor in 
clinical practice.  
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1.1. Principles of magnetic resonance imaging (MRI) 
 
1.1.1 Basic Physics of MRI 
 
Nuclear magnetic resonance (NMR) provides a non-invasive means of constructing a 
spatial representation human tissue in vivo and relies on the magnetic properties of 
certain atomic nuclei. Nuclei with an odd number of protons and neutrons possess 
the property of spin and, since atomic nuclei are electrically charged, their spinning 
motion produces a magnetic moment in the direction of the spin axis.  The strength 
of the magnetic moment is a property of the type of nucleus: since hydrogen nuclei 
(1H) possess the strongest magnetic moment and are present in high abundance in 
biological material, 1H-imaging is the most widely used MRI procedure.  
In the absence of an externally applied magnetic field, thermal motion causes the 
magnetic moments of individual nuclei to have random orientations (Figure 1.1 (a)). 
However, if an externally supplied magnetic field B0 is imposed, the magnetic 
moments have a tendency to align with the external field ( Figure 1.1 (b)).  
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a)       b) 
 
Figure 1.1: (a) A collection of spinning protons in the absence of an externally 
applied magnetic field. The magnetic moments have random orientations. (b) An 
external magnetic field B0 is applied which causes the nuclei to align themselves in 
one of two orientations with respect to B0. 
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The spin axes are not exactly aligned with B0, they precess around B0 with a 
characteristic angular frequency as shown in Figure 1.2.  
 
                                                             
Figure 1.2: A magnetic moment precessing around B0. Its path describes the surface 
of a cone. 
 
The angular precession frequency depends on the strength of the magnetic field 
according to the Larmor equation: 
ω = γB0    
where γ  is the gyromagnetic ratio of the nucleus; B0 is the external magnetic field 
given in Tesla and ω is the precessional, or Larmor, frequency in radians per second. 
The equation shows that the precession frequency increases linearly with the 
magnetic field strength.  
 
 24
In order to detect a signal from 1H nuclei, radio frequency (RF) energy must be 
applied in the form of a magnetic field (B1) rotating at the Larmor frequency. This 
causes M to rotate away from its equilibrium orientation parallel to B0 towards the x-
y plane.  
The angle through which M has rotated away from the z-axis is known as the flip 
angle: the flip angle is proportional to the strength and duration of B1. A 180o pulse 
rotates M into an orientation anti-parallel to B0. If the B1 field is applied indefinitely, 
M tilts away from the z-axis, through the x-y plane towards the negative z direction, 
and finally back towards the x-y plane and z-axis (where the process begins again) 
(McRobbie et al., 2005). Figure 1.3. 
 25
 
 
 
Figure 1.3: Top: the effect of RF radiation on the net magnetization M is to produce 
a component of M, Mx-y, orthogonal to B0. M is tilted from its original longitudinal 
z-axis orientation, parallel to the direction of the external magnetic field B0, into the 
transverse x-y plane. Bottom: an illustration of flip angle, which is the angle through 
which M has rotated away from the z-axis. Figure after  Mike Puddephat 2005.  
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Figure 1.4 (a) shows the situation after a RF pulse is applied that causes the net 
magnetization vector M to flip by 90 degrees. M lies in the x-y plane and continues 
to precess about the B0 direction. M will induce an electromotive force (voltage) in a 
receiver coil. This is the principle of NMR signal detection. It is from this received 
RF signal that an MR image can be constructed. Figure 1.4(b) shows a graph of the 
voltage or signal induced in a receiver coil verses time. Such a graph, or waveform, 
is termed the free induction decay (FID). The magnitude of the generated signal 
depends on the number of nuclei contributing to produce the transverse 
magnetization and on the NMR relaxation times. 
 
(a)                                   (b) 
Figure 1.4: (a) After a 90 degree RF pulse, M lies in the x-y plane and rotates about 
the z-axis. The component of M in the x-y plane decays over time. An alternating 
current, producing the voltage signal shown in Figure (b), is induced in the receiver 
coil. Figure after Mike Puddephat 2005. 
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1.1.2 Relaxation Processes 
The return of M to its equilibrium state (i.e. aligned parallel to B0) following an RF 
pulse is known as relaxation, which is influenced by three processes: the longitudinal 
T1 relaxation, transverse T2 relaxation and signal decay caused by magnetic field 
inhomogeneities. T1 relaxation (also known as spin-lattice relaxation) is the 
realignment of spins (and so of M) with the external magnetic field B0 (z-axis). T2 
relaxation (also known as T2 decay, transverse relaxation or spin-spin relaxation) 
governs the irreversible decrease of the x-y component of M. 
1.1.2.1 T1 relaxation 
Following termination of an RF pulse, nuclei will dissipate their excess energy as 
heat to the surrounding environment (or lattice) and revert to their equilibrium 
orientations. Realignment of the nuclei along B0, through a process known as 
recovery, leads to a gradual increase in the longitudinal magnetization. The time 
taken for the nuclei to relax back to the equilibrium state depends on the rate that 
excess energy is dissipated to the lattice. Figure 1.5. 
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Figure 1.5: T1 is the time taken for the Mz magnetization to recover to 63% of its 
equilibrium value following a 90o pulse. Mz represents the component of the net 
magnetization parallel to the main magnet field B0.  
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1.1.2.2 T2 relaxation 
While nuclei dissipate their excess energy to the lattice following an RF pulse, the 
magnetic moments also interact with each other causing a decrease in transverse 
magnetization. Each nucleus is influenced by the fluctuating magnet fields produced 
by its neighbours, causing transient changes in the Larmor frequency resulting in a 
loss of phase coherence. The resulting decrease in Mxy (which does not involve the 
emission of energy) is generally considered to be an exponential decay with time 
constant T2: T2 is the time it takes for the transverse magnetization to decay to 37% 
of its original magnitude in the absence of magnetic field inhomogeneities. Figure 
1.6. 
It is virtually impossible to construct an NMR magnet with perfectly uniform B0. 
Much additional hardware is supplied with NMR machines to assist in producing a 
homogenous B0 field. However, it is inevitable that an NMR sample will experience 
different B0's across its body so that nuclei within the sample (that exhibit spin) will 
exhibit different precessional frequencies (according to the Larmor equation). 
Immediately following a 90o pulse, all regions within the sample will have Mx-y 
coherent. However, as time goes on, phase differences across the sample will evolve 
due to nuclei precessing at different frequencies. These phase differences will 
increase with time and the vector addition of these out of phase moments will 
progressively reduce Mx-y. 
Therefore in addition to decay governed by the T2 time constant, there is an 
additional contribution to the decay of the Mxy from magnetic field inhomogeneities, 
and the overall signal decay is described by a time constant T2* which characterizes 
dephasing due to both B0 inhomogeneity and transverse relaxation.  
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Figure 1.6 T2 is the time taken for the transverse magnetization to drop to 37% of its 
initial size in the absence of magnetic field inhomogeneities. 
Field gradients and spatial localisation 
In MRI, a field gradient is a linear variation in B0 produced by pulsing current in 
special gradient coils, which can produce field gradients in 3 orthogonal directions 
corresponding to the x, y and z axes. Since the Larmor frequency is linearly 
dependent on B0, the application of field gradients causes the Larmor frequency to be 
dependent upon position: this is the basis of spatial discrimination in MRI. 
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1.1.3 MRI Pulse Sequences 
 
A pulse sequence is an appropriate combination of one or more RF pulses and 
gradients with intervening periods of recovery. A pulse sequence is characterized by 
several parameters, of which the main ones are the TR, TE, flip angle, the number of 
excitations (NEX), bandwidth and acquisition matrix. 
1.1.3.1 Spin Echo Pulse Sequence 
In order to obtain signal with a T2 dependence rather than a T2* dependence, the 
spin-echo (SE) pulse sequence is used which reverses the effects of B0 
inhomogeneity on Mx-y. The SE sequence is the most commonly used pulse sequence 
in clinical imaging. It comprises 2 RF pulses - the 90o pulse that creates the 
detectable magnetization and the 180o pulse that refocuses it at TE. The selection of 
TE and TR determines resulting image contrast.  
The SE sequence is shown pictorially in Figures 1.7 and 1.8. Figure 1.7 is a graph of 
pulsed RF and received signal verses time, while Figure 1.8 is a phase diagram of the 
magnetization vector M. After a 90o pulse, a signal is produced which decays with 
T2* characteristics. This is illustrated by the top right ellipse in Figure 1.7 which 
shows three spins at different phases due to their different precessional frequencies. 
The fastest spin is labelled f and the slowest s. At time TE/2, an 180o pulse is applied 
to the sample (see bottom left ellipse in Figure 1.8) which causes the three spins to 
be reflected about the x axis. After this, the order of the spins is reversed with the 
fastest lagging behind the others. At time TE, the spins become coherent again so 
that a signal (known as the spin echo) is produced. 
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If a further 180o pulse is applied at time TE/2 after the peak signal of the first spin 
echo, then a second spin echo signal will form at time TE after the first spin echo. 
The peak signal amplitude of each spin echo is reduced from its previous peak 
amplitude due to T2 dephasing which cannot be reversed by the 180o pulses. Figure 
1.9 shows how the signal from a spin echo sequence decays over time. A line drawn 
through the peak amplitude of a large number of spin echoes describes the T2 decay, 
while individual spin echoes exhibit T2* decay. 
Signal strength decays with time to varying degrees depending on the different 
materials in the sample. Different organs have different T1s and T2s and hence 
different rates of decay of signal.  
 
Figure 1.7: Formation of a spin echo at time TE after a 90o pulse. Figure after Mike 
Puddephat 2005. 
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Figure 1.8: Dephasing of the magnetization vector by T2* and rephasing by an 180o 
pulse to form a spin echo. Figure after Mike Puddephat 2005. 
 
 
Figure 1.9: Decay of signal with time in a spin echo sequence. Figure after Mike 
Puddephat 2005. 
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Spin-echo sequences can produced both T1- or T2-weighted contrast according to 
the choice of TR and TE. The repetition time (TR) is the time between 2 consecutive 
90o RF pulses and determines the amount of T1 relaxation occurring between them. 
The longer the TR, the more the longitudinal magnetization is recovered. For short 
TRs (< 1s), tissues with short T1 have greater signal intensity than tissues with a 
longer T1 at a given TR. A long TR allows more magnetization to recover and thus 
reduces the degree of T1-weighting in the image contrast. Thus a pulse sequence 
with short TR and short TE produces a T1-weighted image. Conversely, a long TE 
and long TR will allow almost complete T1-relaxation, but allow considerable T2 
signal decay, resulting in a T2-weighted image.  
In short TR T1-weighted images, tissues that have short T1 relaxation times (such as 
fat) present as bright signal. Tissues with long T1 relaxation times (such as cysts, 
cerebrospinal fluid and oedema) show as dark signal. In T2-weighted images, tissues 
that have long T2 relaxation times (such as fluids) appear bright. 
In cerebral tissue, differences in T1 relaxation times between white and grey matter 
permit the differentiation of these tissues on heavily T1-weighted images. Proton 
density-weighted images also allow distinction of white and grey matter, with tissue 
signal intensities mirroring those obtained on T2-weighted images. In general, T1-
weighted images provide excellent anatomic detail, while T2-weighted images are 
often superior for detecting pathology. 
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1.1.3.2 Gradient Recalled Echo Pulse Sequences 
Gradient recalled echo (GRE) sequences, which are significantly faster than SE 
sequences, differ from SE sequences in that there is no 180o refocusing RF pulse. In 
addition, the single RF pulse in a GRE sequence is usually switched on for less time 
than a 90o pulse, in order to obtain an adequate signal-to-noise ratio (SNR) despite a 
short TR used to reduced the total scan time. Depending upon the TE and TR, the 
GRE sequence produces T1- or T2*-weighted contrast at the expense of the SNR 
which drops due to incomplete relaxation and magnetic susceptibility variations. At 
the interface of bone and tissue or air and tissue, there is an apparent loss of signal 
that is heightened as TE is increased. Nevertheless, GRE sequences are widely used 
for obtaining T1-weighted images for a large number of slices or a volume of tissue 
in order to keep scanning times to a minimum. GRE sequences are often used to 
acquire T1-weighted 3D volume data that can be reformatted to display image 
sections in any plane.  
1.1.3.3 FLAIR (Fluid attenuation inversion recovery) 
FLAIR uses a variation on the SE sequence called “inversion recovery”, which has 
an extra 180º RF pulse separated by the inversion recovery time (TI) before the 90º 
pulse. 
The action of the inversion RF pulse is to invert the starting magnetization, which 
then returns to its equilibrium value (M0) according to T1 relaxation (Figure 1.10). 
TI is chosen so that when the 90° pulse is applied, there is no longitudinal 
magnetization to be flipped into the x-y plane from liquid (Figure 1.11). 
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Figure 1.10: (a) Initially the nuclear spins are aligned along z and (b) a 180º pulse 
inverts the magnetization. Note that no transverse magnetization is produced at this 
stage (c,d) T1 relaxation occurs and at the chosen inversion time TI  a 90º pulse is 
applied to generate the MR signal. 
. 
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Figure 1.11: TI is chosen so that the 90° pulse is applied at the null point of fluid. 
 
Thus fluid signals are suppressed in FLAIR imaging, meaning that in brain imaging, 
CSF appears dark, and does not produce a strong signal that may contaminate that 
from adjacent parenchyma. 
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1.1.3.4 Diffusion-weighted imaging 
Diffusion phenomena are the consequence of a microscopic random molecular 
motion, known as Brownian motion. Due to molecular thermal energy, each particle 
in a fluid is constantly moving and is occasionally struck by other molecules. With 
every hit, a particle changes direction randomly, so that, over time, its path can be 
described as a random walk. In free water, molecular diffusion is isotropic, i.e. 
independent of direction. In biological tissues the situation is different because 
diffusing molecules may be reflected, or have their mobility interrupted, by the 
interactions with the cell membranes and other intracellular and extracellular 
structures. Therefore, water diffusion becomes anisotropic, meaning that the 
molecular motion is restricted or hindered by cellular structures in a geometrically-
dependent manner. 
The most common method for producing diffusion-weighted contrast is the pulse 
gradient spin echo (PGSE) method. It consists of a 90° - 180° pair of RF pulses (i.e. 
an SE sequqnce) with large and equal field gradients placed on either side of the 
180° pulse (Figure 1.12). 
The first 90° pulse excites the sample, whilst the second 180° pulse reverses the 
phase of the spins and refocuses the magnetization. In the absence of motion or 
diffusion of the water molecules, the dephasing that occurs after during the first 
gradient pulse is exactly rephased after the 180° pulse and the signal will be 
unchanged. If, instead, there is a random motion of the spins between dephasing and 
rephasing, then the refocusing of the spins is incomplete and there is a loss in the 
transverse magnetization and a reduction in the signal amplitude (Schaefer et al., 
2000). The extent of this attenuation depends on: 1) the diffusion properties of the 
tissue and 2) the magnetic field and the time during which the diffusion process takes 
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place. As a result, where there is free water movement, for example, cerebral spinal 
fluid or in areas of vasogenic oedema, there is a drop in signal. Where there are 
regions of water trapping, for example within swollen cells in areas of cytotoxic 
oedema, there is an increase in signal. In summary, structures with fast (high) 
diffusion are dark, because they are subject to greater signal attenuation, whereas 
structures with slow (low) diffusion are bright (Le Bihan et al., 1992). 
 
 
 
 
 
Figure 1.12: Basic pulsed gradient spin echo (PGSE) sequence for diffusion-
weighted imaging (DWI). Diffusion-weighting gradients of strength GDiff, duration δ, 
and spacing ∆ are applied during each TE/2 period. The diffusion-weighted echo is 
sampled at the time t=TE when the spin echo is formed. The diffusion attenuation is 
only dependent on the parameters GDiff, ∆, and δ but does not depend on t1. Large 
gradient amplitudes are highly advantageous because their use means that the TE can 
be minimized reducing signal loss by T2 decay. Figure after Mike Puddephat 2005. 
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Since the signal change with DWI is also dependent on the underlying T2-weighted 
signal, it is not possible to use DWI signal changes alone to quantify diffusion 
process. Instead the gradient of the signal intensity obtained with different degree of 
diffusion-weighting (b value) is plotted. This yields the diffusion coefficient, which 
is a measure of all random motional processes such as diffusion and incoherent flow. 
In practice what we measure in PGSE is not the free-water (unrestricted) diffusion 
coefficient: since diffusion is frequently reduced by microscopic tissue structures 
which hinder the free motion of eater molecules, in vivo we usually refer to apparent 
diffusion coefficient (ADC). 
In areas of increased diffusion (vasogenic oedema) there is an increase in ADC, and 
DWI signal intensity is decreases. In areas of restricted water diffusion (e.g. 
cytotoxic oedema) ADC decreases and DWI signal intensity increases. To reiterate: a 
high value of D (the self diffusion constant of the tissue) or ADC implies rapid 
motion and therefore low signal in DWI. The corresponding ADC map will be bright 
(McRobbie et al., 2005). 
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1.1.3.5 Perfusion-weighted imaging  
 
Perfusion is a term that has different meanings to different professionals.  
Biotechnologists use it to mean the process of keeping tissues alive in a solution 
containing all the vital nutrients. In cardiology, perfusion means the use of artificial 
blood pumps to propel open-heart surgery patients' blood through their body tissue, 
replacing the function of the heart while the cardiac surgeon operates.  In imaging, 
perfusion is the process of nutritive delivery of arterial blood to a capillary bed in the 
biological tissue (McRobbie et al., 2005). 
There are three measures commonly used to quantify perfusion using MRI or other 
imaging techniques: cerebral blood volume (CBV), cerebral blood flow (CBF) and 
mean transit time (MTT). Often these terms are prefixed with “r” (rCBV, rCBF and 
rMTT), since it is difficult to quantify them absolutely and it is usually preferable to 
find a ratio between the ipsi- and contra-lateral sides.  
There has been much development in the study of blood flow in animals. Since the 
late 1960s the use of plastic, radioactive microspheres was introduced for 
measurement of regional organ perfusion (Rudolph and Heymann, 1967). In 1968 
Makowski et al.(Makowski et al., 1968) the microsphere method was used 
extensively to measure regional blood flow in laboratory animals. Small diameter 
microspheres injected into the left atrium distribute throughout the body and become 
trapped in capillaries of target tissue based on regional blood flow patterns. The 
quantity of microspheres lodged in the tissue of interest is proportional to the 
reference blood flow sample and allows the calculation of regional blood flow in 
ml/g/min (Bartoli et al., 2008). Using this technique, radioactive-labelled 
microspheres have been used to determine relative blood flow in both acute and 
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chronic preparations. In acute experimentation, these microspheres may slightly 
underestimate relative blood flow due to the difference in density between 
radioactive-labelled microspheres and erythrocytes (Hale et al., 1988). Fluorescent-
labelled microspheres are more useful for chronic experimentation, do not pose 
health risks for investigators, and avoid the high disposal costs of radioactive tissues 
and cadavers (Hale et al., 1988; Hoffmann et al., 2002).  
In the neurological field, numerous imaging techniques have also been developed 
and applied to evaluate brain hemodynamics. The main imaging techniques 
dedicated to brain hemodynamics are positron emission tomography (PET), single 
photon emission computed tomography (SPECT), dynamic perfusion computed 
tomography (PCT), MRI dynamic susceptibility contrast (DSC), MRI dynamic 
contrast enhanced (DCE) and arterial spin labeling (ASL) (Wintermark et al., 2005). 
All these techniques give similar information about brain hemodynamics in the form 
of parameters such as cerebral blood flow (CBF) or cerebral blood volume (CBV). 
They use different tracers diffusible or non diffusible, endogenous or exogenous and 
have different technical requirements.  
Positron emission tomography is able to quantify blood flow and different PET 
tracers are available. Among them, 150 labeled-water has the major advantage of 
being freely diffusible and its short half-life (2.1 min) allows sequential 
measurements with a low radiation dose for patients. However, it has the 
disadvantage of a poor signal-to-noise ratio, which hinders its use in clinical routine 
(Merlet et al., 1993). It is mainly used to assess myocardial blood flow (Sheikine and 
Di Carli, 2008).  
Single photon emission computed tomography (SPECT) using technetium-99m 
hexamethylpropylene amine oxime (99mTc-HMPAO) is a well-recognized method of 
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detecting changes of cerebral perfusion (Lee et al., 2003). SPECT perfusion agents 
such as [123I]IMP, [99mTc]HMPAO, [99mTc]ECD have been successfully used to 
detect various cerebrovascular diseases such as stroke, Parkinson disease, 
Huntington's disease, epilepsy, dementia, and psychiatric disorders (Saha et al., 
1994). Furthermore, a reduction in blood flow in the parietal and temporal regions is 
considered to be the definitive SPECT finding in Alzheimer disease (Nitrini et al., 
2000). 
 Dynamic CT perfusion imaging uses equipment available in most radiology 
departments to measure the first pass of a bolus of iodinated contrast medium. The 
method has been used to study the hemodynamics in acute stroke and has been 
validated in animal and human studies (Nabavi et al., 1999; Wintermark et al., 2001). 
Perfusion CT provides an imaging correlate for tumour vascularity that can be used 
to discriminate benign and malignant lesions, indicate tumour aggressiveness, reveal 
occult tumour and improve the delineation of tumours during radiotherapy planning, 
and can also be used as a functional assessment of tumour response to therapy 
(Miles, 2006). Perfusion CT is used for preoperative grading of gliomas with relative 
CBV being the best parameter correlating with glioma grades (Ellika et al., 2007). A 
study showed good correlation between CT and MR for CBF and MTT abnormalities 
(Eastwood et al., 2003).  However, dynamic CT perfusion studies presently are 
limited to either a 1-cm- or a 2-cm-thick section of tissue per acquisition, depending 
on whether a single-slice CT scanner or a multislice CT scanner is used.  
Perfusion-weighted imaging (PWI) methods can be divided into three main 
categories depending on the type of imaging used to acquire the data. First, dynamic 
susceptibility contrast MRI (DSC-MRI) is a first pass technique that uses rapid 
measurement of T2- or T2*-weighted signal change after injection of a bolus of 
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paramagnetic compound (i.e. gadolinium-based contrast material). This technique 
will be described with more detail bellow. Secondly, dynamic contrast enhanced 
MRI (DCE-MRI) is based on the T1-weighted signal change produced after an 
interval of 5-10 minutes following injection of gadolinium-based contrast material. 
Thirdly, arterial spin labeling (ASL) uses water as a freely diffusible endogenous 
tracer of the blood’s entry into the imaging volume (Jenkinson et al., 2007).  It tags 
proton in the arterial blood supply with a magnetic “label”, then images the required 
slices with or without the labelling. When images are then acquired from slices in the 
brain, there will be a very small signal loss compared with unlabelled images. This is 
because there is an inflow enhancement even in the capillaries (McRobbie et al., 
2005). The label decays in only 4-5 seconds due to T1 relaxation of the blood 
protons, so EPI id used for the image acquisition. There are several different ASL 
techniques, differing mainly in the way they apply the labelling and control pulses, 
one of them is flow-sensitive alternating inversion recovery (FAIR). In the FAIR 
labelled images, an inversion pulse is applied to the whole brain before a single-slice 
EPI image is acquired. For the control experiment the inversion pulse is applied only 
to the imaged slice. In the labelled image, inverted protons in the arterial supply are 
carried into the capillary bed of the imaged slice and exchange with protons in the 
tissues. It has been shown that the FAIR signal may depend on hemodynamic 
parameters other than perfusion, the most important one being transit delays of 
labelled spins to the observed tissue. (Schepers et al., 2004). Although a slower 
technique with poor signal to noise ratio, it is completely non-invasive and can be 
repeated as often as required without having to wait for the excretion of the 
gadolinium (McRobbie et al., 2005) (Tofts, 2004). Although recent developments at 
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3T have improved results, ASL has been slow to emerge as a technique sufficiently 
robust for clinical use.  
Since DSC-MRI was the technique used in this thesis, the method will now be 
described in greater detail.  DSC-MRI required rapidly repeated multi-slice imaging 
during the first pass of a gadolinium bolus: a volume of tissue, usually only a few 
slices, is imaged repeatedly using an echo-planar imaging (EPI) sequence. After a 
few images have been collected to establish an equilibrium baseline, a bolus of 
gadolinium is injected as rapidly as possible. During the first pass through the 
intracranial circulation the high concentration of gadolinium in the vasculature 
causes a reduction of T2 and T2* in the surrounding tissue, which is seen as a drop 
in signal intensity on T2-weighted or T2*-weighted images (Figure 1.13 A, B and 
C). This drop in signal is proportional to the concentration of the contrast agent and 
the tissue vascularity. The whole imaging sequence takes no more than 2-3 minutes. 
The signal intensity curve is used to determine the rCBV, the relative cerebral blood 
flow (rCBF), the time of arrival, the time to peak and the mean transient time (MTT) 
of the contrast–agent (Chaskis et al., 2006). The time to peak is not often used in 
brain tumours since, unlike in infarcts, there rarely is much of a delay in blood flow 
within tumours (Price, 2007). In the evaluation of intracranial mass lesions, CBV 
appears to be the most useful parameter (Cha et al., 2002) and this will be 
emphasized in this thesis.  
The passage of gadolinium causes changes in both T2 and T2* so that both spin-echo 
and gradient-echo echo-planar imaging sequences provide robust measurements of 
CBV. Originally gradient-echo EPI sequences were used for DSC-MRI since they 
are most sensitive to changes in T2*. When a paramagnetic contrast agent such as 
gadolinium passes through the cerebral vascular system, it induces differences in 
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local magnetic susceptibility between vessels and the surrounding tissue. Although 
the vascular space is a small fraction of the total tissue blood volume, this 
compartmentalization of contrast agent causes targeted paramagnetism within the 
intravascular spins as well as the surrounding spins within a given voxel. Thus, both 
intravascular and extravascular spins experience a reduction of T2* that leads to a 
large transient signal loss of approximately 25% in normal white matter with a 
standard dose of contrast (0.1 mmol/kg of body weight). T2-weighted spin-echo 
images are less sensitive and require double or even quadruple the contrast agent 
dose to give substantial signal changes during the bolus passage. On the other hand, 
gradient-echo sequences are more prone to magnetic susceptibility artefacts. Thus, 
when imaging lesions near brain-bone-air interfaces such as the temporal lobes or 
posterior fossa where these artefacts are more pronounced, spin echo sequences may 
be preferable. However, artefacts in gradient-echo images can be overcome to a large 
extent by reducing the slice thickness (Cha, 2004).  
There should be at least five images in the baseline section for analysis purposes: 
since a bolus injection in the antecubital vein typically takes 8-10 seconds to reach 
the brain, the injection should be started soon after the start of the imaging sequence. 
It is useful to have a power injector as an injection rate of 3-5ml s-1 is necessary to 
achieve a good bolus which may be difficult by hand. Repeated imaging of the 
volume should continue for a total of 2-3min. 
In the absence of recirculation and contrast leakage, CBV is proportional to the area 
under the contrast concentration-time curve (Figure 1.13). The effects of the 
recirculation can be reduced by manually choosing the beginning and end of the 
bolus. While the area under the corrected contrast concentration-time curve is 
proportional to the CBV, this approach does not yield an absolute measurement. It is 
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therefore necessary to express the measurement relative to a standard reference, 
usually contralateral white matter. We refer to this as relative CBV (rCBV).  
In order to determine absolute values of CBV and CBF it is necessary to deconvolve 
the arterial input function (AIF) from the tissue response curve, in order to account 
for variations in the bolus shape and timing. However, the unambiguous 
determination of an appropriate AIF is challenging, the calculations may be sensitive 
to the details of the analysis method, and the necessary assumptions regarding the 
relationship between contrast agent concentration and signal intensity may be hard to 
support in the atypical microvascular environment of many tumours (Calamante et 
al., 1999). For this reason absolute quantification of these haemodynamic measures 
was not attempted in the present work.  In this thesis we will consider only the use of 
rCBV acquired with DSC MRI. 
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Figure 1.13:  T2*-weighted image before the injection of  a bolus of gadolinium, B) 
T2* weighted with drop of signal intensity, during the first pass of the gadolinium 
bolus, C) signal-intensity/time graph showing the arrival of the first pass of the bolus 
of gadolinium (closed arrow) and peak height (open arrow). D) rCBV map of a right 
frontal low-grade glioma. 
 
 
 
 
 
A)                                                      B) 
 C)                                                          D)  
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Analysis of DSC-imaging cerebral perfusion data is frequently performed at a 
clinical workstation using proprietary software. Most software produce pixel-by-
pixel maps of the required parameters and use colour scales for display (Figure 1.13 
D). 
 
 
1.2. Conclusion 
This chapter has described the basic physics of MRI and the most relevant sequences 
used within this thesis. Chapters 3, 4, 5 and 6 while describe the application of 
conventional, perfusion- and diffusion-weighted MR imaging in patients with 
histology proven low-grade gliomas in order to provide further insight into their role 
in the management of patients with these brain tumours. 
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Chapter 2 
An introduction to brain gliomas and clinical applications of magnetic resonance 
imaging 
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 2.1 Brain Gliomas  
 
The World Health Organization (WHO) classification (Kleihues et al., 1993; 
Kleihues P, 2000; Louis et al., 2007) classifies brain tumours in: neuroepithelial 
tumours, cranial nerves tumours, meningial tumours, lymphoma and haemopoietic 
tumours, germ cell tumours, tumours of the sellar region and metastatic tumours. 
The fourth edition of the World Health Organization (WHO) classification of 
tumours of the central nervous system, published in 2007, lists several new entities, 
including angiocentric glioma, papillary glioneuronal tumour, rosette-forming 
glioneuronal tumour of the fourth ventricle, papillary tumour of the pineal region, 
pituicytoma and spindle cell oncocytoma of the adenohypophysis. However when 
the work of this thesis was performed, WHO classification of 2000 was used. In the 
2000 edition the main contribution to brain gliomas was the recognition of the 
emerging role of molecular diagnostic approaches to tumour classification, as in the 
distinct subtypes of glioblastoma and the already clinically useful 1p and 19q 
markers for oligodendroglioma. 
In this thesis the main attention will be given to gliomas, which are the commonest 
neuroepithelial tumours. They can be divided into three types, depending on the cell 
type they originate from: astrocytomas, oligodendrogliomas and oligoastrocytomas 
(Behin et al., 2003). These gliomas can be subdivided in low (WHO grades I and II) 
and high-grade tumours (WHO grades III and IV), reflecting their biological 
behavior. 
 52
Caution should be taken when interpreting the incidences for each subtype of 
astrocytoma, oligodendroglioma and oligoastrocytoma, since histologic sampling 
error and inter- or intrapathologist variability could result in tumour 
misclassification.  
The use of diffusion- and perfusion-weighted imaging has been used widely in the 
study of brain gliomas. Section 2.2 of this chapter will further consider this 
technique and its neuroimaging characteristics will be discussed in detail.  
 
 
 
 
2.1.1 Astrocytomas 
Astrocytomas account for approximately 75% of glial tumours. They can be divided 
into four histological grades, according to the WHO classification, ranging from the 
benign pilocytic astrocytomas (Grade I) to glioblastoma multiforme (Grade IV), 
which is the most malignant astrocytic tumour. The incidence of the various types of 
astrocytic tumours varies with age. In children, most of these are relatively benign 
tumours (pilocytic or low-grade astrocytomas), in young adults low-grade 
astrocytomas predominate, whereas anaplastic astrocytomas have a peak incidence 
around 40 years and glioblastoma multiforme usually occurs after 40 years (Behin et 
al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 53
2.1.1.1  Pilocytic astrocytomas (WHO grade I) 
These are well-circumscribed, potentially resectable lesions with a low proliferative 
potential and a predilection for the posterior fossa. They are primarily seen in 
children and are rare in adults. Infratentorial pilocytic astrocytomas in adults are 
frequently mistaken for haemangioblastomas, which have a similar appearance and 
represent the commonest primary intra-axial tumour below the tentorium cerebelli in 
adults (Jäger et al., 2007).  
Clinical Features 
Seizures are uncommon, since the tumour does not usually involve the cerebral 
cortex. These tumours produce focal neurological deficits, such as macrocephaly, 
headache, endocrinopathy or increased intracranial pressure. Other focal deficits 
could be present, depending on the location of the tumour.  
 
Neuroimaging  
Pilocytic astrocytomas are primarily a paediatric neoplasm and rare in adults. They 
are well circumscribed tumours and have a predilection for the posterior fossa, optic 
nerves and hypothalamus. Infratentorial pilocytic astrocytomas in adults may be 
mistaken for haemangioblastomas. On computed tomography (CT) they often appear 
as a cystic lesion with an eccentric mural nodule that strongly enhances after the 
administration of contrast agent. On MRI, low-grade astrocytomas are typically 
hyperintense on T2-weighted images. They usually have a significant cystic 
component and show enhancement which can be nodular or ring-like (Dixon et al., 
2007).  
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2.1.1.2 Diffuse astrocytomas (WHO grade II) 
Diffuse astrocytomas are infiltrating low-grade tumours which occur typically in the 
hemispheres of young adults, involving cortex and white matter. However, focal, 
grossly circumscribed lesions can also occur. They have less well defined borders 
than pilocytic astrocytomas and contrast enhancement is usually absent. WHO grade 
II astrocytomas show a low mitotic activity but have a propensity to progress to a 
higher histological grade. They represent 10 to 15% of all astrocytomas and the 
median survival time is 10 years (Osborn, 1994).  
Clinical Features 
Seizures are a common manifestation of the tumour. Other abnormalities could be 
present, such as speech difficulties, changes in sensation, vision or some motor 
changes as well. The focal deficit will depend on the location of the tumour. With 
frontal lobe tumours, changes in behaviour or personality may be the presenting 
feature. 
Neuroimaging 
CT and MRI: These tumours appear as an iso- or hypodense mass on CT and could 
show calcification in up to 20% of cases. MRI (and specifically a FLAIR sequence) 
is better in defining the extent of the low-grade gliomas, which are hyperintense on 
FLAIR and T2-weighted images (Figure 2.1.) and hypo/isointense on T1-weighted 
images. The margins of many tumours are poorly delineated. Cystic degeneration 
may happen, but necrosis is usually absent. Haemorrhage is also unusual and the 
surrounding oedema is generally kept to a minimum (Osborn, 1994). Gadolinium 
enhancement is not common in low-grade diffuse astrocytomas, but tends to appear 
during tumour progression. Low-grade astrocytomas have higher ADC than 
oligodendrogliomas (Tozer et al., 2007). 
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Figure 2.1. WHO grade II astrocytoma. Axial T2W (A), FLAIR (B) images showing 
a left frontal hyperintense mass lesion with well defined borders and small cystic 
areas. On the trace-weighted DWI (C) the tumour is not very conspicuous as T2 
effects and diffusion effects cancel each other out. On the ADC map (D) the glioma 
is easily identified as an area of increased diffusivity compared to normal brain 
parenchyma.  
 
 
 
A)         B) 
C)        D) 
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2.1.1.3 Anaplastic astrocytomas (WHO grade III)  
WHO grade III astrocytomas represent 33% of astrocytomas and they are usually 
present in patients from 40 to 60 years old (Osborn, 1994). They have an increased 
mitotic activity and may arise from low-grade astrocytomas, but are also diagnosed 
at first biopsy, without indication of a less malignant precursor lesion. The prognosis 
is poor, with a medium survival of 2 years (Osborn, 1994). These tumours have a 
tendency for malignant progression to glioblastoma multiforme.  
Clinical Features 
Symptoms are similar to those of patients with diffuse astrocytoma. Not infrequently 
there are signs of a recurrent glioma, following initial resection of a diffuse low-
grade astrocytoma. These signs could be increasing neurological deficits, seizures 
and/or intracranial pressure. 
Neuroimaging 
The tumour can appear very heterogeneous, with haemorrhagic areas within the 
tumour and show more extensive infiltration of the peri-tumoural tissues than WHO 
Grade II lesions (Wilms et al., 2005; Young and Knopp, 2006).  This leads to a 
mixed density and intensity on both CT and MRI (Figure 2.2). These tumours 
usually have moderate mass effect. Contrast enhancement is usually observed and a 
rapid tumour growth with development of oedema may lead to mass shifts and 
increased intracranial pressure (Figure 2.2). Anaplastic astrocytomas typically spread 
through white matter tracts. In most cases, tumour cells can be found in the 
oedematous areas and beyond it as well (Earnest et al., 1988; Watanabe et al., 1992). 
These tumours can also spread along the ependyma, leptomeninges and the 
cerebrospinal fluid (Grabb et al., 1992).  
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Figure 2.2. WHO grade III astrocytoma.  Coronal T1W post-contrast image (A) of a 
frontal irregularly enhancing mass with some cystic areas, which appears 
inhomogeneous on T2W images (B). The latter showing also associated vasogenic 
oedema at the posterior margin of the tumour. There is marked mass effect with 
midline shift. The trace-weighted DWI (C) and ADC map (D) appear 
inhomogeneous with cystic areas and more restricted diffusion peripherally. 
 
A)     B) 
 
 
 
 
 
 
 
 
 
 
 
 
C)     D)  
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2.1.1.4 Glioblastoma multiforme (WHO Grade IV)  
Glioblastoma multiformes (GBMs) show poorly differentiated, often highly 
pleomorphic glial tumour cells with vascular proliferation and necrosis. 
Unfortunately it has the worst prognosis and is also the commonest primary 
intracranial neoplasm in adults (Nelson and Cha, 2003).  These rapidly growing, 
highly mitotic tumours may arise from pre-existing lower grade astrocytomas or 
occur de novo (particularly in older patients) (Behin et al., 2003).  
Clinical Features 
Unless the neoplasm has developed from a WHO grade III tumour, the clinical 
history is usually less than 3 months in more than 50% of cases (Kleihues P, 2000). 
Patients can present with seizures and non-specific neurological symptoms, but the 
most aggressive aspect is the rapid development of increased intracranial pressure.    
Neuroimaging  
This tumour may arise from pre-existing lower grade astrocytomas or occur de novo 
(primary), particularly in older patients (Behin et al., 2003). Vasogenic oedema and 
contrast enhancement are usually much more extensive than in anaplastic 
astrocytomas. These tumours have a mixed density on CT and a mixed signal mass 
in MRI.  
Tumour necrosis is a hallmark of GBM and appears on MRI as areas of non-
enhancing T1 hypointensity, frequently surrounded by a ring-like zone of contrast 
enhancement (Figure 2.3). Studies have showed that this contrast area does not 
represent the outer tumour border, as infiltrating glioma cells can be easily identified 
within a 2cm margin (Burger and Bigner, 1988). Enhancement is usually strong and 
very inhomogeneous. Intratumoural haemorrhage of different ages contributes to the 
heterogeneous MR appearance of GBM. Their usual location is the cerebral white 
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matter, particularly the frontal and temporal lobes. Basal ganglia involvement may 
be present. GBMs have a rapid, infiltrative growth and tend to extend through the 
corpus callosum into the contralateral hemisphere, creating the image of a bilateral 
symmetrical lesion, known as “butterfly glioma”. A small number of GBMs may 
show evidence of subarachnoid seeding.   
The presence of true multiple independent gliomas is controversial. Post-mortem 
studies may not show a connection between apparently multifocal gliomas, as the 
infiltrating cells are often small and undifferentiated. However, this type of tumours 
can only be proven by molecular markers which will allow a distinction between 
tumours of common or independent origin (Kleihues P, 2000). 
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Figure 2.3. Glioblastoma multiforme. Axial T2W (A) and FLAIR (B) images show a 
large fronto-temporal glioma hyperintense on both sequences. It is predominately 
solid with central necrotic area and ring-like contrast enhancement seen on the T1W 
post-gadolinium show central enhancement (C).  Relative CBV map (D) shows areas 
of high perfusion corresponding to the enhancement region. DWI (E) and ADC map 
(F) show an area of increased diffusion in the necrotic area and restricted diffusion 
around it.  
 
 
 
 
 
A)          B)                 C) 
 
 
 
 
 
 
 
 
 
 
D)            E)                            F) 
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2.1.2 Oligodendrogliomas 
The most recent World Health Organization (WHO) classification system divides 
oligodendrogliomas into low-grade (Grade II) and high-grade (Grade III, anaplastic) 
tumours. These neoplasms account for up to 33% of all adult gliomas (Perry, 2001 ) 
and have a longer survival. Prayson et al showed a overall survival for 
oligodendrogliomas of 5- and 10-year of 71% and 63%, respectively (Prayson et al., 
2000). The majority of the tumours occur in adults with a peak incidence of the 5th 
and 6th decade. They are diffusely infiltrating neoplasms which are found almost 
exclusively in the cerebral hemispheres, most commonly in the frontal lobes, and 
typically involving subcortical white matter and cortex. Both low- and high-grade 
oligodendroglial tumours may contain regions of increased vascular density with 
finely branching capillaries that have a “chicken wire” appearance (Jäger et al., 
2007). 
 2.1.2.1. Oligodendrogliomas (WHO grade II) 
They are typically located in the cerebral hemispheres and are well-differentiated, 
diffusely infiltrating tumours. Although oligodendrogliomas can arise in any cerebral 
lobe, the frontal lobe is involved in 50-65% of the patients (Kros et al., 1994).  
Clinical Features 
The most common signs are seizures and headache. Patients may present with a long 
pre-operative history of neurological sings and symptoms.  
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Neuroimaging 
Typically on CT scan, oligodendrogliomas appear hypodense or isodense (Margain 
et al., 1991). On MRI the lesions appears well as a demarcated hypointensity in T1 
and hyperintense in T2W images, usually located in the cortex and subcortical white 
matter. Peritumoural oedema is usually mild or absent; cystic changes and tumour 
haemorrhages may also be seen. Up to 90% of oligodendrogliomas contain visible 
calcification on CT, which can be central or peripheral. (Ricci, 1999) On MRI, areas 
of calcification may be more difficult to appreciate due to the variable appearance of 
calcification. Intratumoural calcification appears typically T2 hypo- and T1 
hyperintense but intratumoural haemorrhage, which occurs uncommonly in 
oligodendrogliomas, may have a similar appearance.  Contrast enhancement is 
variable and often heterogeneous. In general WHO grade II tumours do not 
infrequently exhibit some contrast enhancement whereas WHO grade III 
oligodendrogliomas may not enhance (White et al., 2005). However many studies 
have used contrast enhancement as a radiological marker of malignancy in gliomas 
(Daumas-Duport et al., 1997; Mihara et al., 1995; Pierallini et al., 1997). Relative 
CBV measurements derived from DSC MR imaging were significantly higher in 
low-grade oligodendrogliomas than in astrocytomas (Cha et al., 2005) (Figure 2.4). 
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Figure 2.4. WHO grade II oligodendroglioma. Axial T2W image (A) and colour 
rCBV map (B) showing areas of increased rCBV (yellow and red areas) within the 
inhomogeneous left frontal tumour. 
 
 
 
 
 
 
A)        B)  
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2.1.2.2 Anaplastic oligodendrogliomas (WHO grade III) 
These tumours are defined as an oligodendroglioma with focal or diffuse histological 
features of malignancy and a less favourable prognosis. They manifest preferentially 
in adults in the 5th decade.  
Clinical Features  
The signs are similar to those of oligodendrogliomas. However some patients may 
present with long standing signs suggesting a pre-existing tumour of lower grade.  
Neuroimaging 
Due to the presence of necrosis and cystic degeneration, intratumoural calcification 
and haemorrhages, these tumours may have heterogeneous patterns. Cysts appear 
hypointense in T1W and hyperintense in T2W images, whereas intratumoural 
calcification (as well as some stages of haemorrhage) appears typically T2 hypo- and 
T1 hyperintense. The MRI appearances of these elements are the same as for 
oligodendrogliomas. Contrast enhancement on CT and MRI is usual (Figure 2.5).   
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Figure 2.5. Oligodendroglioma, grade III: T2W (A) and FLAIR (B) show a large 
right frontal tumour that involves the cortex. It is predominantly solid with irregular 
enhancement, seen on the T1W after the use of contrast (C) and cystic areas, 
hyperintense on T2W and FLAIR and hypointense on T1W. rCBV map (D) shows 
areas of high perfusion on the periphery of the tumour and around the cystic areas. 
DWI and ADC maps (E, F, respectively) demonstrate areas of increase diffusion 
corresponding to the cysts and reduced diffusion around it.  
 
 
 
 
 
A)          B)       C) 
 
 
 
 
 
 
 
 
 
 
D)        E)                              F) 
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2.1.3 Oligoastrocytomas  
Oligoastrocytomas are heterogeneous tumours that have molecular features that 
overlap with either oligodendrogliomas or astrocytomas. It has been reported that at 
least half of the tumours that were originally classified as oligodendrogliomas would 
have astrocytic cells in it (Ruseell and Rubistein, 1989; Russell and Rubistein, 1989). 
 
2.1.3.1 Oligoastrocytomas (WHO grade II) 
Specific data on oligoastrocytomas are rare and difficult to interpret because of their 
imprecise definition, especially on the proportion of oligodendroglial and astrocytic 
cell population required to make their diagnosis and because in most trials, these 
tumours were studied together with anaplastic oligodendrogliomas or astrocytomas. 
Their chemosensitivity seems similar to that for anaplastic oligodendrogliomas (Kim 
et al., 1996).   
Clinical Features 
The symptoms and signs are similar to those described for astrocytomas and 
oligodendrogliomas, most commonly epileptic seizures. 
Neuroimaging 
These tumours demonstrate no special features that would allow a reliable distinction 
from oligodendrogliomas. On MRI the lesions appears as a hypointensity mass in T1 
and hyperintense in T2W images, usually located in the cerebral hemisphere. 
Calcifications and contrast enhancement may be present. Figure 2.6. 
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Figure 2.6. WHO grade II oligoastrocytoma. Axial T2W (A), FLAIR (B) 
images showing a right parietal hyperintense mass lesion.T1W post contrast 
(C) shows hypointense lesion without enhancement.  
 
 
 
 
 
 
 
 
A)             B)     C)   
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2.1.3.2 Anaplastic oligoastrocytomas (WHO grade III) 
These tumours also have a mixture of two distinct neoplastic cell types that 
morphologically resembles the tumour cells in oligodendroglioma and astrocytoma. 
In addition they have histological features of malignancy, such as increased 
cellularity, nuclear atypia, pleomorphism and increased mitotic activity.  
Clinical Features 
In some cases, the clinical history of patients with WHO grade III may be long 
before diagnosis, especially with the presence of seizures, suggesting a pre-existing 
low-grade glioma.  
Neuroimaging 
On MRI the lesions appears as hypointense in T1W and hyperintense in T2W 
images, usually located in the cerebral hemisphere. Usually these tumours show 
contrast enhancement on CT and MRI. Figure 2.7. 
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Figure 2.7. WHO grade III oligoastrocytoma. Axial T2W (A), FLAIR (B) images 
showing a hyperintense mass lesion in the left temporal lobe. Sagittal  (C) and 
coronal T1W (D) shows hypointense lesion which enhances after the use of contrast 
(D) .  
 
 
 
 
 
 
     
A)                                                  B) 
 
 
 
 
 
 
 
 
 
 
 
 
C)         D)  
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2.2 The use of advanced MR techniques in brain tumours 
In this section information will be given about the new techniques used to assess 
brain tumours. Diffusion- and perfusion-weighted imaging were used routinely in 
this thesis so more details will be given to these techniques.   
 
2.2.1 Diffusion-weighted imaging 
 
One of the commonest applications of diffusion-weighted imaging (DWI) in the 
assessment of tumours is in differentiating between types of cystic lesions. It is 
particularly useful in distinguishing between epidermoids, where the thick content of 
the cyst restricts the diffusion of water, and arachnoid cysts where diffusion is free 
(Hakyemez et al., 2003). Similarly, the viscous content of abscesses can be 
differentiated from cystic tumours (Lai et al., 2002). 
Both the cellularity and matrix composition of tumour will influence ADC values. 
Studies have shown that tumours frequently have higher ADC values compared with 
normal brain (Bulakbasi et al., 2003; Kono et al., 2001b). The regions with the 
highest ADC values are within cysts or areas of necrosis.  
Sugahara et al. (Sugahara et al., 1999a) showed that tumour cellularity correlated 
well with the minimum ADC value of the gliomas and that diffusion-weighted MRI 
with EPI is a useful technique for assessing the tumour cellularity and grading of 
gliomas. It has been shown that there is an inverse relationship between cellularity 
and ADC (Kono et al., 2001b; Sugahara et al., 1999a). Significant differences have 
been reported between the ADC values of low- and high-grade gliomas. These 
differences appear to be partly related to the differences in cell density of these 
tumours (Guo et al., 2002; Kono et al., 2001a; Sugahara et al., 1999a). Additionally, 
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a substantial portion of the tumour volume is made up of extracellular matrix. One of 
the components of the extracellular matrix is a macromolecule called  
glycosaminoglycan, which have been localized to the tumour cell–associated 
extracellular matrix of astrocytic glial tumours in vivo (Sadeghi et al., 2003). The 
glycosaminoglycans are highly hydrophilic and tend to attract sodium, which is 
osmotically active, causing the shift of large amounts of water. Therefore, 
glycosaminoglycans are thought to influence the water content of the extracellular 
matrix and thus the value of ADC.  In the same study (Sadeghi et al., 2003) the 
author showed that the extracellular matrix in gliomas likely contributes to 
differences in the ADC values between high- and low-grade glial tumours. In high-
grade tumours there is also vasogenic oedema produced due to defects in the blood -
 brain barrier, which causes an increase in the ADC and a decrease in the DWI signal 
(Figure 2.8).   
Several studies have sought to characterize tumour subtype and grade using ADC 
values. Minimum tumour ADC has been shown to distinguish histological tumour 
grade (Kono et al., 2001a; Tozer et al., 2007). This advanced technique provides 
further information which contributes towards the clinical management of brain 
gliomas.  
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A)         B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Diffusion weighted brain image (A) and ADC map (B) showing a right 
lesion with well defined borders with increased diffusion causing hypointensity on 
DWI and high signal on the ADC map in the basal ganglia.  
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2.2.2 Diffusion Tensor Imaging (DTI) 
Diffusion tensor imaging is a modification of DWI that is sensitive to the preferential 
diffusion of brain water along white matter tracts (anisotropic diffusion). This 
technique was not included in this thesis, since it was not available at our institution 
at that time.  
DTI can detect subtle changes in white-matter tracts in the brain (Le Bihan, 2003). In 
brain tumours, DTI can be used to differentiate normal white matter, oedematous 
brain tissue, and enhancing tumour margins (Sinha et al., 2002), provide a useful 
method of detecting occult white matter invasion by gliomas (Price et al., 2003) and 
is also able to delineate the tumour margins of gliomas (Price et al., 2006). Diffusion 
anisotropy is reduced in cerebral lesions due to the loss of structural organisation 
(Price et al., 2003). The measurement of fractional anisotropy allows prediction of 
histological characteristics such as cellularity, vascularity, or fibre structure in 
gliomas (Beppu et al., 2003). In addition, DTI may help determine if the fibres are 
displaced, infiltrated, or disrupted by the tumour (Witwer et al., 2002). Such 
knowledge could contribute to the selection of surgical indications. Ideally, DTI can 
be combined with functional neuroimaging methods (Krings et al., 2001) to allow 
mapping of individual anatomofunctional connectivity. This information would be 
useful for surgical planning of patients with brain glioma. 
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2.2.3 Perfusion-weighted imaging 
 
In order to grow, tumours must develop networks of vascular supply. The 
development of neoangiogenic networks is promoted by an interaction of various 
pro- and antiangiogenic tissue factors. One important factor is vascular endothelial 
growth factor (VEGF). Its expression is promoted by nutrient-deficient states, such 
as tissue hypoxia or hypoglycemia, that occur as tumour cells in rapidly growing 
pathologic tissues expand beyond the limits of diffusion of nutrients from the native 
capillaries (Shweiki et al., 1992). VEGF promotes growth of new endothelial cells by 
stimulating cell division (Provenzale et al., 2006) and has been demonstrated to be a 
prognostic marker in gliomas (Abdulrauf et al., 1998). Glioma progression is 
strongly dependent on the development of new vascular network that occurs 
primarily by angiogenesis (Jouanneau, 2008). However, the new vessels formed in 
tumours are characteristically abnormal, having increased tortuosity (Jain et al., 
2002), lack of maturity (as evidenced by decreased amounts of perivascular cells) 
and increased permeability to macromolecules due to the presence of large 
endothelial cell gaps (Hashizume et al., 2000). The result is that the neovessels often 
have both abnormal flow characteristics and abnormal permeability that can be 
exploited as potential surrogate markers for the evaluation of tumour growth. Thus, 
regions of high rCBV are thought to reflect areas of high capillary density, which is a 
reflection of tumour aggressiveness. 
The use of MR perfusion is ideally suited to neuro-oncology where imaging studies 
of angiogenesis and tumour vasculature further our understanding of tumour biology. 
In gliomas, perfusion MRI has been used to characterize WHO grade (Cha et al., 
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2005), tumour genotype (Jenkinson et al., 2006), guide biopsy (Cha et al., 2002) and 
provide prognostic information (Law et al., 2006a).  
Most studies in the literature have focused on the role of perfusion MRI to determine 
pathology grade in mixed gliomas or astrocytomas. Values of rCBV correlate well 
with conventional angiographic assessment of tumour vascular density and 
histopathology measures of angiogenesis such as microvessel density and vascular 
endothelial growth factor expression, (Maia et al., 2005; Sugahara et al., 1998) 
which reflects the histopathological finding of increasing neovascularization with 
grade. Relative cerebral blood volume tends to increase with increasing tumour 
grade (Law et al., 2003; Lev et al., 2004). However, low-grade oligodendrogliomas 
can have significantly higher rCBV when compared to low-grade astrocytomas, 
reflecting the increased vascularity and “chicken wire” vessels seen on histology 
(Cha et al., 2005). In studies of mixed gliomas, the rCBV in oligodendrogliomas 
may render perfusion MRI-based tumour grading less accurate (Lev et al., 2004; Xu 
et al., 2005).  
Caution should be taken with extravascular leakage of gadolinium through defective 
tumour vessels as it can influence rCBV measurements. The choice of the cut-off 
points in the analysis of the time-signal-intensity curve is important to minimize 
confounding effects of contrast leakage (Cha et al., 2002).  
Even though perfusion has been widely used in the study of brain tumours, the 
choice of inclusion or exclusion of intratumoural vessels is often not explicitly 
stated. As this can have a confounding effect, the significance of intratumoural 
vessels upon rCBV measurements was investigated in chapter 3 of this thesis.    
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 2.2.4 MR Spectroscopy 
Proton MR Spectroscopy (MRS) analyses the biochemistry of a brain tumour and 
provides semiquantitative information about major metabolites (Law, 2004; Vlieger 
et al., 2004). A common pattern in brain tumours is a decrease in N-AcetylAspartate 
(NAA), a neuronspecific marker, and Creatine (Cr) and an increase in choline (Cho), 
Lactate (Lac), Lipids (L). The concentration of Cho is a reflection of the turnover of 
cell membranes (due to accelerated synthesis and destruction) and is more elevated 
in regions with a high neoplastic activity. Lactate (Lac) is the end product of 
nonoxidative glycolysis and a marker of hypoxia in tumour tissue.  This is of 
increasing interest as tumour hypoxia is now recognized as a major promoter of 
tumour angiogenesis and invasion. Lac is probably associated with viable but 
hypoxic tissue, whereas mobile Lipids are thought to reflect tissue necrosis with 
breakdown of cell membranes. 
The choice of echo time (TE) is a important technical considerations for performing 
MRS. It can be short (20 to 40ms), intermediate (135 to 144 ms) or long (270 to 
288ms). MRS with a short TE has the advantage of demonstrating additional 
metabolites which may improve tumour characterisation, such as myo-Inositol, 
glutamate/glutamine (Glx) and lipids, but is hampered by baseline distortion and 
artefactual NAA peaks. Intermediate echo times have a better defined baseline and 
quantification of NAA and Cho is more accurate and reproducible. Long echo times 
lead to a decrease of signal to noise. 
 MRS is presently a sensitive but not very specific technique. Single voxel 
acquisition provides good quality spectra but is prone to sampling errors. Chemical 
shift imaging is technically more demanding but covers a larger volume of tissue. 
MRS was not used in the work of this thesis. 
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2.2.5 PET 
Imaging of brain tumours with 18F-FDG was the first oncologic application of PET 
(Di Chiro et al., 1988; Patronas et al., 1982; Wong et al., 2002).18F-FDG is actively 
transported across the BBB into the cell, where it is phosphorylated. 18F-FDG uptake 
is generally high in high-grade tumours. The prognostic value of 18F-FDG uptake is 
well established: High uptake in a previously known low-grade tumour establishes 
the diagnosis of anaplastic transformation (De Witte et al., 1996).  
However, recent studies have demonstrated amino acid PET tracers are more 
sensitive than 18F-FDG in imaging recurrent tumours and in particular recurrent low-
grade tumours. They are also promising in differentiating between recurrent tumors 
and treatment-induced changes (Chen, 2007). 
Amino acid PET tracers are important for the imaging of brain tumours because of 
the high uptake in tumour tissue and low uptake in normal brain tissue and it is 
generally increased in malignant transformation (Isselbacher, 1972). The best-
studied amino acid tracer is 11C-methionine (Herholz et al., 1998).  
One of the main application of PET in brain tumours is to differentiate radiation 
necrosis and tumour re-growth (Langleben and Segall, 2000). In previously treated 
patients, 18F-FDG PET can be helpful in differentiating recurrent tumor from 
radiation necrosis. Amino acid tracers are promising in that they are more sensitive 
in imaging brain tumors. Amino acid tracers may also be useful in distinguishing 
recurrent tumors from radiation necrosis, although further studies are needed (Chen, 
2007).  
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2.2.6 Functional MRI 
Blood oxygen level-dependent (BOLD) imaging detects changes in regional cerebral 
blood flow during various forms of brain activity. Paradigms using motor tasks, 
language and speech productions, and memory are able to show activation of 
relevant cortical areas. The main use of fMRI in tumour imaging is the pre-operative 
localization of eloquent cortical regions which may have been displaced, distorted or 
compressed by the tumour (Vlieger et al., 2004). This can improve the safety of 
surgery and allow for a more radical resection. If possible fMRI should be combined 
with DTI in order to minimise intra-operative injury to white matter tracts connected 
to eloquent cortical areas. 
The use of fMRI was not included in this thesis. 
 
2.3 Physiology-based MR imaging in the differential diagnosis and 
grading of glial tumours 
 
2.3.1 Distinguishing between astrocytomas and oligodendrogliomas 
 
As mentioned before, there is evidence that perfusion- and diffusion-weighted 
imaging can help to differentiate low-grade astrocytic from oligodendroglial 
tumours.  WHO grade II oligodendrogliomas have significantly higher rCBV than 
WHO grade II astrocytomas (Cha et al., 2005) which concurs with the histological 
findings of increased vascular density in oligodendrogliomas. Measurement of the 
ADC, using a whole tumour histogram analysis, appears promising for the 
differentiation of astrocytomas from oligodendrogliomas. The latter have 
significantly lower ADC values than astrocytomas, reflecting a higher cellular 
density and differences in tumour matrix composition (Tozer et al., 2006).  
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2.3.2 Distinguishing between low-grade and high-grade gliomas 
 
As already stated in this chapter several studies investigated the potential of 
advanced MR imaging to distinguish between low- and high-grade gliomas. Studies 
have shown (Yang et al., 2002)  that mean maximum rCBV values correlated closely 
with histological grades. A recent study of 160 primary cerebral gliomas showed that 
rCBV measurements significantly increased the sensitivity and positive predictive 
value of conventional MR imaging in glioma grading (Law et al., 2003). Perfusion-
weighted imaging had a sensitivity of 95% and positive predictive value of 87% for 
distinguishing low-grade from high-grade gliomas when an rCBV threshold of 1.75 
was used (Law et al., 2003).    
The role of DWI in differentiating high-grade from low-grade gliomas remains 
unclear.  Initial reports were encouraging and  showed lower ADC measurements in 
high-grade lesions (Sugahara et al., 1999a; Yang et al., 2002) but these have not been 
confirmed in subsequent studies (Sadeghi et al., 2003).  
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 2.4 Controversies in the management of gliomas 
 
The treatment of malignant gliomas is still very challenging. Despite considerable 
progress in the treatment of these tumours with combinations of surgery, 
radiotherapy, and chemotherapy, these efforts have not been curative (Dunn and 
Black, 2003). Brain gliomas are characterized by aggressive proliferation and 
expansion and tumour invasion into distant brain tissue, which makes it more 
difficult to find an effective treatment.  
At time of presentation, most patients require treatment with corticosteroids because 
of peritumoral edema and resultant mass effect (Moots, 1998). Also, dexamethasone 
has been shown to inhibit or stimulate growth of rat 9L gliosarcoma and decrease the 
expression of vascular endothelial growth factor (VEGF), an important mediator of 
tumor-associated angiogenesis (Badruddoja et al., 2003; Maia et al., 2005). Because 
of the potential for long-term complications of corticosteroids, the lowest therapeutic 
dose should be used. In our cohort none of patients received corticosteroids.  
Early studies used either whole brain radiation or regional fields. Although proven 
effective, these methods did increase the incidence of late radiation-induced brain 
injury (Vick and Paleologos, 1995). Newer technologies such as conformal fields 
with 3-dimentional planning and intensity-modulated radiation therapy  delivers the 
desired dose of radiation to the target, limiting exposure to the surrounding normal 
brain parenchyma. The limitation of radiotherapy is that ideally it has to be 
administrated only at once, and finding the best timing remains a challenge in the 
management of these patients. However, there is also evidence for the beneficial 
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effect of radiosurgery on the survival of patients with high-grade gliomas (Szeifert et 
al., 2007). 
The use of chemotherapy for the treatment of malignant brain tumours remains 
controversial. A study published in 2002 (Stewart, 2002) showed that the addition of 
chemotherapy to radiation demonstrated significant but modest improvement in 
survival at one year of 6 percent. The Medical Research Council (MRC) in the 
United Kingdom performed a large randomized trial comparing radiation therapy 
alone with radiation treatment followed by adjuvant treatment with PCV 
(procarbazine, CCNU and vincristine) (MRCBT, 2001). Despite enrolling 673 
patients, no difference was detected in survival between the two groups. A more 
recent study showed that concurrent use of temozolomide with external beam 
radiation followed by adjuvant temozolomide treatment has proven to be better than 
radiation alone and is now the standard of care for patients with newly diagnosed 
GBM (Gilbert and Armstrong, 2007). 
Finally there are also controversies between oncologists, neurosurgeons and 
pathologists in the surgical management of patients with brain glioma. The 
indications of resection still remain a matter of debate, especially because of the 
frequent location of these tumours within eloquent brain areas - thus with a risk to 
induce a permanent postoperative deficit (Duffau, 2006). Oncologists are often 
worried that a resection might damage these eloquent areas and pathologists are 
concern that the whole tumour might not be removed as most tumours recur within 
2cm from the enhancing edge (Hochberg and Pruitt, 1980). However, all those risks 
can be minimezed by the use of neuronavigation with functional MRI and diffusion 
tensor imaging during the surgical treatment. As previously described, the main use 
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of intra operative fMRI is the localization of eloquent cortical regions which may 
have been displaced, distorted or compressed by the tumour. DTI can be used to 
delineate glioma margins and regions of infiltration.  
Previous work has shown that surgical resection may improve outcome (Gilbert and 
Armstrong, 2007). The study by LaCroix evaluated 417 consecutive patients with 
malignant gliomas who underwent tumour resection with the pre-operative intent to 
perform a complete resection (Lacroix et al., 2001). After accounting for prognostic 
factors such as age and performance status, they found that patients who had 
undergone at least a 98% resection by volumetric analysis had a statistically 
significant improvement in overall survival. 
The cohort of patients used in this thesis had a median survival of 3.76 years. This 
survival is much shorter than in other centres, as it will be discussed in the following 
chapters.  Patients from our cohort only received treatment when transformation was 
diagnosed. Since early surgical treatment have shown to improve survival in patients 
with brain glioma, it would be interesting to confirm this in our centre. 
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2.5 Conclusion  
 
Magnetic resonance imaging plays an important role in the detection and evaluation 
of brain tumours. Conventional MR imaging has principally served the role of 
showing the neoplasm, distinguishing tumours from other pathologic processes, and 
depicting basic signs of tumour response to therapy, such as change in size and 
degree of contrast enhancement. In the past few years, however, a number of 
advanced MR imaging techniques have been developed that provide new methods 
for the assessment of brain tumours. Diffusion- and perfusion-weighted imaging 
provide additional physiological information, helping to differentiate tumour 
subtypes and grades and may even provide prognostic information, contributing to 
the management of brain gliomas.  
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Chapter 3 
Methodological Study: Implication of intratumoural vessels in glioma perfusion 
imaging 
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3.1 Introduction  
 
As described in the previous chapters, dynamic susceptibility contrast-enhanced 
(DSC) MR perfusion imaging has become an important technique for studying brain 
tumours.  
The choice of techniques for data acquisition, post-processing and analysis may 
influence rCBV quantification.  Gradient-echo echo-planar imaging (GE-EPI) pulse-
sequences are more sensitive to larger vessels than spin-echo (SE) EPI methods and 
provide better differentiation between histopathological tumour grades (Sugahara et 
al., 2001).   
Wetzel et al (Wetzel et al., 2002) found  inter- and intra-observer reproducibility for 
intratumoural rCBV was best  when  the highest CBV from several regions of 
interest was chosen, and highlighted the importance of excluding large vessels.  
Inclusion or exclusion of intratumoural vessels is often not explicitly stated in glioma 
perfusion studies, some investigators focussing on exclusion of peri-tumoural vessels 
(Sugahara et al., 2001). The significance of intratumoural vessels for rCBV 
measurements has, to our knowledge, not been formally examined.   
In this short chapter we studied the influence of intratumoural vessels on rCBV 
characterization in three histological categories of low-grade glial tumours: 
astrocytomas (ACs), oligodendrogliomas (ODs) and oligoastrocytomas (OAs). 
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3.2 Technique and results  
 
34 patients with low-grade gliomas, comprising 21 ACs; 8 ODs and 5 OAs had DSC 
imaging using gradient-echo EPI (TR =1200 ms, TE = 40 ms, flip angle 20º, 26 cm 
FOV, 96x128 matrix; slice thickness 5 mm) at 1.5 Tesla (GE Healthcare, Waukesha, 
WI) with a bolus of 0.1mmol/kg body weight  gadoterate meglumine at  5 ml/sec. 
Colour maps of rCBV were generated with FuncTool 1.9 (GE Healthcare, 
Waukesha, WI) and analyzed by 2 neuroradiologists, reaching a consensus for 
placement of regions of interest (ROIs).  At least 6 intratumoural ROI with a size of 
9 pixels were placed over areas showing most elevated CBV on colour perfusion 
maps.  Blood vessels within the tumour were identified on unprocessed perfusion 
images acquired between the time points of maximum arterial and venous signal 
drop. Slices above and below intratumoural vessels were   viewed to identify 
potentially confounding partial volume effects from large vessels.  We used 2 
different methods for selecting the ROI with the maximum intra-tumoural CBV: 
method 1 included and method 2 excluded ROIs situated over intratumoural blood 
vessels and associated partial volume effects. The rCBVmax was then obtained by 
dividing the highest intra-tumoural CBV by the mean CBV obtained from a contra-
lateral normal appearing white matter ROI. Figure 3.1. 
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Figure 3.1. T2*-weighted image during maximum arterial signal intensity drop (A) 
and rCBV map (B) in low-grade OD, demonstrating the position of ROIs used to 
calculate rCBVmax. Method 1 (open arrowhead, posterior ROI in the left cerebral 
hemisphere, overlying an intratumoural vessel) and method 2 (closed arrowhead, 
anterior ROI in the left cerebral hemisphere, lying outside intratumoural vessels). 
The mean CBV from contralateral normal-appearing white matter (ROI in the right 
cerebral hemisphere) was used to normalize the data for each method. White circles 
have been superimposed on the original colour-coded ROIs generated by FuncTool. 
Mean rCBVmax obtained for each group with each method are shown in Table 1.1.  
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Table 3.1 rCBVmax obtained using methods 1 and 2 [Mean (range)]. 
(AC=astrocytoma, OA=oligoastrocytoma, OD=oligodendroglioma). 
 ALL 
TUMOURS 
AC (N=21) OA (N=8) OD (N=5) 
 
Method 
1 
4.01 (1.54 – 
6.99) 
3.30 (1.54 – 
6.65) 
5.33 (3.07 – 
6.65) 
5.04 (2.74 – 
6.99) 
Method 
2 
1.63 (0.70– 
3.51)* 
1.44 (0.70 - 
2.46) 
1.53 (1.26 – 
1.94) 
2.21 (1.47 – 
3.51) 
 
* p <0.001 method 1 vs. method 2; Wilcoxon test 
 
Method 1 yielded higher mean values and wider ranges than Method 2 in all 3 
histological tumour types, particularly in OA and OD. For the patient group as a 
whole, there was a significant difference between mean rCBVmax obtained using 
each method (p < 0.001, Wilcoxon test). Ordinal regression was used to assess the 
relationship of rCBVmax and tumour histology, categorized in 3 groups (0: OA, 1 
AC, 2 OD). Only method 2 showed a significant association between rCBVmax and 
the risk of being in a histological category with higher ordinate.  Using method 2, the 
odds-ratio of being in a higher category was 4.25 (95% Confidence interval, lower: 
1.19 and upper 15.14) for each additional unit rCBV increment (p=0.026). Method 1 
did not demonstrated a significant association between rCBVmax and the risk of 
being in a higher category (p= 0.638).  
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3.3 Discussion 
 
Several studies have demonstrated increased rCBV in high-grade gliomas compared 
to low-grade tumours (Cha et al., 2005; Hakyemez et al., 2005; Law et al., 2003; Lev 
et al., 2004; Spampinato et al., 2007; Sugahara et al., 2001; Yang et al., 2002). There 
is, however, considerable variation in the reported rCBV values for low- and high-
grade tumours (Table 3.2). In SE-EPI DSC imaging, transverse relaxation rates peak 
at a vessel diameter of 1-2 µm whereas  in GE-EPI DSC imaging they  plateau at 3-4 
µm and then remain independent of vessels size, which explains the lower rCBVs 
found with SE techniques (Sugahara et al., 2001).   Differences may also be due to 
variations in the histological types of LGG examined and inclusion or exclusion of 
intratumoural vessels in the analysis, often not specified. 
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Table 3.2. rCBVmax for low-grade (LGG) and high-grade (HGG) gliomas reported 
in previous DSC-MR perfusion studies.   
AUTHOR  
(REFERENCE) 
N LGG MEAN 
RCBVMAX  
(RANGE)  
HGG MEAN 
RCBVMAX  
(RANGE) 
HISTOLOGY TECHNIQUE 
Law (Law et al., 
2003) 
160 2.14  
(0.77-9.84) 
5.18  
(0.96–9.80) 
Histology not 
specified 
GE-EPI 
Law (Law et al., 
2006a) 
35 2.41  
(0.37-5.96) 
 AC, OA, OD GE-EPI 
Sugahara (Sugahara 
et al., 2001) 
25 1.21 
 (0.43-1.34) 
1.22  
(0.54-2.31) 
4.86  
(0.61-9.71) 
2.90  
(0.56-9.30) 
AC, OD, 
GBM* 
GE-EPI 
SE-EPI 
Hakyemez 
(Hakyemez et al., 
2005) 
33 3.32  
(1.40-8.68) 
6.50  
(2.39-18.60) 
AC, OA, OD, 
GBM 
GE-EPI 
Yang (Yang et al., 
2002) 
17 1.74  
(1.17-2.45) 
6.10  
(1.70-16.17) 
AC. OA,OD, 
GBM 
SE-EPI 
Cha (Cha et al., 
2005) 
25 0.92 (0.48-1.34) 
AC 
3.68 (1.29-9.24) 
OD 
 AC and OD GE-EPI 
 
GE-EPI 
Spampinato 
(Spampinato et al., 
2007) 
22 1.61 5.45 OD and OA GE-EPI 
AC: astrocytoma, OA: oligoastrocytoma, OD: oligodendroglioma, GBM: 
glioblastoma multiforme, GE-EPI: gradient-echo echo-planar imaging,  SE- EPI: 
spin-echo echo-planar imaging. N: number of patients. * All low-grades were 
astrocytomas 
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We demonstrated that inclusion of large intratumoural vessels significantly increases 
rCBVmax values in all types of LGG.  Their identification may be difficult on rCBV 
colour maps alone and necessitates reviewing of unprocessed perfusion data. The 
size of intratumoural vessels clearly identifiable on GE-EPI source data lies in 
millimetre range (approximating the size of peripheral leptomenigeal vessels), 
whereas neo-angiogenetic vessels of gliomas in animal models measure between 40-
250 µm (Sugahara et al., 2001).   
In concordance with previous investigators we found higher rCBVmax in tumours 
with oligodendral elements than in purely astrocytic tumours (Lev et al., 2004), 
explained by the “chicken wire” hypervascularity seen in the former. Cha et al. (Cha 
et al., 2005)  chose intratumoural ROIs with an automated method targeting areas of 
maximum signal decrease during the first pass of the gadolinium-based contrast 
bolus. This method is likely to have incorporated intratumoural vessels and yielded 
mean rCBV for ODs of 3.68. Spampinato et al (Spampinato et al., 2007) presented 
one of the few reports specifying exclusion of large intratumoural vessels  for ROI 
analysis.  Their mean rCBV measurement for a mixed group of low-grade OA and 
OD (1.61) lies between our group mean rCBV measurements of OA (1.53) and OD 
(2.21) using Method 2. We were able to demonstrate significant association between 
maximum intratumoural rCBV values and histopathological classification as AC, 
OD, and OA, but only when using method 2. The influence of intratumoural vessels 
on rCBV measurements in high-grade gliomas, which are naturally subject to greater 
variability, was not part of this study and this could be addressed in future studies. 
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3.4 Conclusion 
Our findings highlight the importance of using a consistent ROI placement 
technique, particularly if rCBV data are to be pooled in multi-centre studies.  As a 
preferred technique we therefore recommend exclusion of intratumoural vessels 
when determining maximum intratumoural rCBV from GE-EPI DSC derived data. 
On the following chapters we use method 2 when analyzing rCBV as it proved to be 
a consistent and reliable technique. 
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Chapter 4 
Relative cerebral blood volume measurements predict malignant transformation in 
patients with low-grade gliomas 
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 4.1 Introduction   
 
Adult supratentorial low-grade gliomas (WHO grade II, 2000) are a heterogeneous 
group of diffusely infiltrating primary brain tumours.  They grow slowly for several 
years but, at an unpredictable time, almost all progress to high-grade (WHO grade III 
or IV) gliomas, which carry a poor prognosis.  
The management of low-grade gliomas (LGG) remains controversial. Although 
some centres treat these lesions aggressively at diagnosis, large population-based 
studies and prospective trials have not produced evidence of improved survival 
following radical surgery or early radiotherapy (Johannesen et al., 2003; van den 
Bent et al., 2005), particularly in young patients presenting with well-controlled 
epilepsy.  
A change in appearance on imaging frequently precedes clinical deterioration, and 
the development of areas of focal contrast-enhancement is the most commonly used 
sign of tumour progression in clinical practice; this has proved a more reliable 
indicator of malignancy in gliomas than border definition, mass effect, necrosis and 
haemorrhage (Daumas-Duport et al., 1997; Mihara et al., 1995; Pierallini et al., 
1997). However, up to one third of malignant gliomas do not enhance (Scott et al., 
2002) and, certain sub-types of low-grade gliomas show enhancement; typically 
gangliogliomas and pilocytic astrocytomas, and occasionally oligodendrogliomas 
(White et al., 2005).  
Vascular proliferation (angiogenesis) is an important histological hallmark of 
malignancy in glial tumours. Pathological contrast enhancement in tumours indicates 
local disruption of the blood brain barrier; this is an indirect marker of angiogenesis 
as the walls of the new vessels may be deficient and more permeable.  
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As described in chapter 2, MR perfusion imaging is a sensitive marker of the 
microvascular density and histological grade of gliomas. Relative cerebral blood 
volume (rCBV) measurements correlate closely with angiographic and histological 
markers of tumour vascularity (Sugahara et al., 1998), and are more elevated in high-
grade than in low-grade gliomas (Aronen et al., 1994; Donahue et al., 2000; 
Sugahara et al., 1998) (Law et al., 2003; Lev et al., 2004; Sugahara et al., 2001; 
Yang et al., 2002). A correlation between rCBV and the expression of vascular 
endothelial growth factor (VGEF) has been demonstrated, using 
immunohistochemical staining of surgical specimens (Maia et al., 2005).  A recent 
study of patients referred for preoperative assessment of low-grade gliomas showed 
that baseline rCBV measurements made prior to surgery correlated inversely with 
the time to subsequent tumour progression (Law et al., 2006a).  
Thus, the purpose of this chapter was to analyze longitudinal MR perfusion imaging 
of conservatively treated low-grade gliomas to determine whether rCBV is a 
predictor of malignant transformation. 
 
4.2 Methods  
 
4.2.1 Patients  
Thirty five patients were recruited sequentially from the neuro-oncology clinic of the 
National Hospital of Neurology and Neurosurgery, in London. The inclusion criteria 
were: (i) histologically confirmed WHO grade II gliomas (Kleihues P, 2000); (ii) no 
previous treatment except biopsy (surgery, radiotherapy or chemotherapy) and (iii) 
age ≥ 18 years. Patients underwent conventional and perfusion imaging at study 
entry, 6 months and 12 months later. For the remainder of the study they were 
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assessed clinically and conventional MR imaging was performed every six months. 
The study was approved by the local research ethics committee and all patients 
provided informed consent. 
 
4.2.2 MRI protocol 
All MR data were acquired with a clinical 1.5 T system (Signa LX, GE Medical 
Systems, Milwaukee, WI, USA). The following images were acquired: 
1) 3D Coronal Spoiled gradient echo (SPGR) sequence [parameters: 
TE=6.4ms; TR=14.4ms; TI=650ms; flip angle 15º; 256 x 256 matrix; 24cm x 
18cm FOV (3/4 phase FOV); slice thickness 1.5 mm, contiguous sections], 
pre- and post-contrast (0.2mmol/kg of gadoterate meglumine  (Dotarem ®)).  
2) 2D Coronal oblique fast spin echo (FSE) fluid-attenuated inversion recovery 
(FLAIR) [TE=161ms; TR=8774ms; TI=2192ms; 256x192 (reconstructed to 
256x256) matrix; 24cm x 24cm FOV; slice thickness 5mm and gap 1.5mm]. 
 
3) Axial Dynamic susceptibility-weighted perfusion contrast-enhanced images 
using a T2*-weighted gradient-echo echo-planar sequence were acquired 
during the first pass of a 0.1mmol/kg  bolus of gadoterate meglumine  
(Dotarem ®), injected at a rate of 5 ml/sec [TE = 40 ms;  TR =1200 ms; flip 
angle 90º; 128 x 92 matrix; 26cm x 26cm FOV; slice thickness 5 mm, 
contiguous sections]. These images were acquired before the post-contrast T1 
weighted images from sequence 1. 
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4.2.3 MRI analysis 
1) Pre- and post-contrast spoiled gradient echo (SPGR) images were analyzed 
by visual inspection in order to assess whether tumour enhancement was 
present and/or different from that visible on the images acquired at the 
previous time point, using Agfa IMPAX PACS system. 
  
2) Dynamic susceptibility-weighted perfusion images were processed off-line 
on Advantage Workstation commercial processing software (Functool, 
General Electric Medical Systems, WI, USA). The beginning and end of the 
first pass bolus was determined by inspection of time-signal intensity curves, 
and care was taken to exclude any recirculation-related signal. For rCBV 
calculations, only the area under the curve of the first pass bolus was 
considered. Colour-coded rCBV maps were generated. For each slice, one 
region of interest (ROI) of 9 pixels was placed within the tumour, on the area 
showing the most elevated CBV on colour perfusion maps, and one more 
ROI was positioned in the contralateral normal white matter. Attention was 
given not to include intra-tumoural or peri-tumoural arteries and veins in a 
ROI, as described elsewhere (Brasil Caseiras et al., 2008).  The maximum 
CBV value of all intra-tumoural ROIs and the mean CBV of the contralateral 
ROIs were calculated (Figure 4.1). The rCBV values were then expressed as 
a ratio of the maximum intra-tumour CBV and the mean CBV in the 
contralateral normal appearing white matter. This approach has been shown 
to provide the best inter-observer and intra-observer reproducibility (Law et 
al., 2003; Wetzel et al., 2002). 
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Figure 4.1:  T2*-weighted image during maximum arterial contrast signal intensity 
drop (A), and rCBV map (B). Note that for the calculation of maximum rCBV value, 
intra- or peri-tumoural vessels were not included (open arrow). An ROI was placed 
on the area showing the most elevated CBV (closed arrow) and also on the 
contralateral white mater. The maximum CBV value of the intra-tumoural ROIs and 
the mean CBV of the contralateral ROIs were calculated. 
 
 
 
 
 
 
 
 
A)         B) 
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4.2.4 Statistical analysis 
Analysis was performed using Stata 9 (Stata Corporation, College Station, TX USA) 
and p<0.05 was considered to be significant.  
At the last individual available follow-up visit, patients were classified into three 
categories of roughly equal sizes: 1) Stable: patients without radiological evidence of 
malignant transformation. These patients’ MRI studies showed either no 
enhancement or stable enhancement of the tumour compared to study entry (n=11), 
2) Progressive: patients with radiological evidence of malignant transformation 
showing one or more new areas of contrast enhancement or increase of previously 
stable enhancement (n=13), and 3) Death (n=11).  
 
1.  Changes in rCBV over time 
The Friedman test was used to analyze the distribution of rCBV at study entry, 6 
months and 12 months, and to assess whether there were significant changes of the 
mean values between these three time points and also between the changes of rCBV 
within 6 and 12 months.  
 
2. Differences between groups  
The Mann-Whitney test was used to determine whether there was a significant 
difference in the median of rCBV values between two groups. The Kruskal-Wallis 
test was used when more than two independent groups were involved. 
 
a) Histological groups 
Relative CBV at each time point were used as dependent variables. Firstly, tumour 
histology was used as the grouping variable and was divided into two groups: the 
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first included tumours with oligodendroglial elements (oligodendrogliomas and 
oligoastrocytomas; total number=13); the second group included pure astrocytomas 
(total number=22). Secondly, tumour histology was used again as a grouping 
variable, but it was divided into three groups: i) oligodendrogliomas (n=8), ii) 
astrocytomas (n=22) and iii) oligoastrocytomas (n=5). 
 
b) Outcome groups 
Relative CBV at each time point were used as dependent variables. Outcome (used 
as the grouping variable) was divided into two groups: those patients without adverse 
event (stable patients, n=11) and those who presented an adverse event 
(transformation and death, n= 24).  
 
3. Association with transformation  
To investigate if rCBV at study entry, 6 and 12 months was associated with 
transformation, independently from histology, age and gender, an ordinal logistic 
multiple regression analysis was repeated for each time points (i.e. study entry, 6 and 
12 months).  Additionally the ordinal logistic analysis was also applied to investigate 
whether changes of rCBV in 6 months or in 12 months were associated with 
transformation.  Firstly, rCBV was modelled individually. Then the rCBV 
parameters that remained significant were modelled together with histology (using 2 
tumour subtypes and 3 tumour subtypes), age and gender.  
The dependable variable was classified in two groups, patients that transformed and 
those who did not. The covariate was rCBV and its changes at each time point.  
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4. Time to transformation analysis  
A Cox regression curve was used to investigate the best predictor of time to 
transformation. Time was measured as years from study entry to transformation. 
Stable patients were censored at last follow-up. The covariates at each time point 
were: rCBV values, histology (first using 2 tumour subtypes and then 3 tumour 
subtypes), age and gender. The same analysis was repeated using changes of rCBV 
between study entry and 6 months and also between study entry and 12 months.  
The same analysis was performed in a subgroup including pure astrocytomas and 
another one including oligodendrogliomas and oligoastrocytomas. 
 
Kaplan Meier curve for the strongest predictor  
A Kaplan Meier curve was produced for the strongest predictor of time to 
transformation. 
A receiver operating characteristic (ROC) analysis was applied to assess which 
variable cut-off at study entry was able to allow the differentiation between patients 
who progressed to high-grade gliomas and those who did not.  
 
4.3 Results   
Patients 
Demographic data are shown on table 4.1. 
Thirty-five patients (mean age: 42; standard deviation (SD) 13.05 ; 24 males and 11 
females) with histology proven WHO grade II gliomas (22 astrocytomas, 8 
oligodendrogliomas and 5 oligoastrocytomas) were studied for a median total 
follow-up length of 2.9 years (range 0.4 – 5.6). All 35 patients had MRI studies at 6 
months after study entry, while 4 (11%) patients failed to attend the 12 months scan 
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(1 patient died, 1 patient went abroad for treatment, and 2 patients clinically 
progressed and dropped out).  Of the patients who had these MRI studies, perfusion 
imaging was not available in 1 patient at study entry, 2 patients at 6 months and 4 
patients at 12 months, due to technical problems.  
Eleven out of 35 patients (31.4%) remained stable during the follow-up, while 13 
patients (37.1%) progressed and 11 (31.4%) died. All deaths were related to tumour 
progression. The median length of follow-up was 2.4 years for the stable (range: 0.5 
– 5.3 years) and 2.0 years for the progressive group of patients (range: 0.5 – 5.5 
years). Patients who died were radiologically followed-up for a median of 2.0 years 
(range: 0.5 – 3 years), but were clinically studied for longer (median 3.9 years; range 
1- 4.8). 
Stable patients only received palliative treatment (mainly anti-epileptic medication) 
during the study. Patients did not receive any aggressive treatment until progression 
to a high-grade glioma had occurred. Twenty-two out of 35 patients (68.5%) were 
treated after transformation, which included surgery in 9 patients, radiotherapy in 16 
patients and chemotherapy in 8 cases. The median time from study entry to treatment 
was 2.4 years (range: 0.6 – 5.5). Only two patients received treatment within the first 
year of the study, but both cases were treatment-free at study entry and 6 months; no 
further MRI data were available after the first 6 months in these two cases. 
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 Table 4.1: Demographic data and rCBV values at study entry, 6 months and 12 
months and its changes within 6 and 12 months. 
Pat 
ID 
Histology Age Gender rCBV 
at 
study 
entry 
 rCBV at 
6m 
rCBV 
Changes 
in 6 
months 
 
rCBV 
at 
12m 
rCBV  
Changes 
in 12m 
1 O 30 F 2.02 3.01 0.99 3.44 0.43 
2 A 51 M 2.46 2.82 0.36 - - 
3 A 30 M 2.00 3.74 1.74 na na 
4 O 57 M 1.94 2.07 0.13 3.29 1.22 
5 OA 25 M 1.28 1.77 0.49 1.86 0.09 
6 A 37 M 0.99 1.78 0.79 na na 
7 A 30 M 0.94 1.94 1.00 - - 
8 O 56 M 2.53 2.86 0.33 3.15 0.29 
9 A 38 M  na 1.66 1.66 1.51 -0.15 
10 OA 48 M 1.26 2.23 0.97 - - 
11 A 56 M 1.04 2.66 1.62 2.25 -0.41 
12 OA 42 F 1.91 2.54 0.63 3.32 0.78 
13 A 58 M 2.24 na na na na 
14 A 29 F 2.38 na  na na na 
15 A 41 M 1.04 1.24 0.20 1.72 0.48 
16 A 34 M 1.56 2.03 0.47 2.3 0.27 
17 A 47 F 1.09 1.35 0.26 1.59 0.24 
18 O 28 F 2.81 4.62 1.81 4.16 -0.46 
19 A 35 M 0.91 1.76 0.85 1.37 -0.39 
20 OA 65 F 1.28 1.57 0.29 1.52 -0.05 
21 A 30 M 1.91 2.17 0.26 2.5 0.33 
22 O 24 M 1.59 2.14 0.55 2.15 0.01 
23 A 52 M 1.37 1.94 0.57 2.43 0.49 
24 O 53 F 1.84 2 0.16 2.01 0.01 
25 O 63 F 1.47 1.96 0.49 1.98 0.02 
26 O 36 M 3.51 4.24 0.73 7.9 3.66 
27 A 60 F 1.14 1.53 0.39 2.7 1.17 
28 A 38 M 0.80 1.43 0.63 1.54 0.11 
29 OA 69 M 1.94 2.35 0.41 2.35 0 
30 A 29 F 1.18 1.73 0.55 1.31 -0.42 
31 A 32 M 1.61 2.66 1.05 2.91 0.25 
32 A 57 F 1.49 2.34 0.85 2.17 -0.17 
33 A 32 M 1.42 1.5 0.08 2.17 0.67 
34 A 39 M 1.79 2.23 0.44 - - 
35 A 29 M 0.70 1.51 0.81 1.68 0.17 
F: female, M: male, A: astrocytoma, O: oligodendroglioma, OA: oligoastrocytoma,  
na: not available due to technical problems, (-): patient failed to attend follow up.  
S: stable, P: progressive, D: death.  
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1.  Changes in rCBV over time 
There were significant changes in the mean values of rCBV between study entry, 6 and 12 
months.  (all p values were < 0.001) and also between the changes of rCBV within 6 and 12 
months (p=0.03). 
The median, mean values, standard deviation and range of rCBV for each time point and the 
change of these parameters within the first 6 and 12 months after study entry are given in 
Table 4.2.  
 
Table 4.2. Mean, median, standard deviation and range of rCBV at each time point and of 
rCBV changes in 6 and 12 months.  
Time point Mean Median Minimum Maximum Std Deviation 
Study Entry rCBV 1.63 1.53 .70 3.51 .63 
6m rCBV 2.22 2.03 1.24 4.62 .79 
12m rCBV 2.49 2.17 1.31 7.90 1.30 
Changes of rCBV  
between SE and 6 months  
.68 .55 .08 1.81 .47 
Changes of rCBV  
between SE and 12 months 
.89 .71 -.94 4.39 .87 
Std: Standard deviation 
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2.  Differences between groups 
a) Histological groups 
At study entry, there was a significant difference (p=0.01) in the median values of rCBV 
between patients with tumours with oligodendroglial elements and those with pure 
astrocytomas. There was also a significant difference between these two groups at 6 (p=0.02) 
and 12 months (p=0.04).  
Similarly there was a significant difference (p=0.01) in the median values of rCBV at study 
entry between patients with oligodendrogliomas, astrocytomas and oligoastrocytomas. There 
was also a significant difference between these three groups at 6 (p=0.04) and 12 months 
(p=0.05).  
Astrocytomas had the lowest rCBV values whereas oligodendrogliomas had the highest 
rCBV values and the rCBV of oligoastrocytomas lay in between. Table 4.3.  
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Table 4.3. Mean, median, standard deviation, and range of rCBV values for patients with 
pathologically proved low-grade gliomas in each histological category. 
Histology  Time point N Mean Median Minimum Maximum Std 
Deviation 
OD Study Entry 
rCBV 
8 2.21 1.98 1.47 3.51 .69 
  
6m rCBV 8 2.86 2.50 1.96 4.62 1.05 
  
12m rCBV 8 3.51 3.22 1.98 7.90 1.94 
AC Study Entry 
rCBV 
22 1.43 1.37 .70 2.46 .53 
  
6m rCBV 22 2.00 1.86 1.24 3.74 .61 
  
12m rCBV 22 2.01 2.17 1.31 2.91 .51 
OA Study Entry 
rCBV 
5 1.53 1.28 1.26 1.94 .36 
  
6m rCBV 5 2.09 2.23 1.57 2.54 .41 
  
12m rCBV 5 2.26 2.11 1.52 3.32 .78 
AC: astrocytomas OD: Oligodendrogliomas, OA: oligoastrocytomas, N: number of cases, 
Std: standard. 
 
 
b) Outcome groups 
There is a borderline significant difference (p=0.55) in the median values of rCBV at study 
entry between patients who had an adverse event (transformation or death) and those who did 
not. Relative CBV values at 6 or 12 months were not able to differentiate patients between 
these two groups.  
Table 4.4 shows the mean, median, standard deviation, and range of rCBV values for patients 
in each clinical-radiological category.  
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Table 4.4. Mean, median, standard deviation, and range of rCBV values for patients with 
pathologically proved low-grade gliomas in each clinical-radiological category. 
Radiological-
Clinical 
Outcome   
Time 
Point   
N Mean Median Minimum Maximum Std 
Deviation 
Stable Study 
Entry 
rCBV 
11 1.32 1.42 .70 1.94 .40 
  
6m 
rCBV 
11 1.93 1.94 1.43 2.66 .42 
  
12m 
rCBV 
11 2.09 2.17 1.31 2.91 .53 
Progressive Study 
Entry 
rCBV 
13 1.99 1.89 .99 3.51 .72 
  
6m 
rCBV 
13 2.52 2.07 1.57 4.62 .97 
  
12m 
rCBV 
13 3.08 2.43 1.51 7.90 1.80 
Dead Study 
Entry 
rCBV 
11 1.55 1.28 .91 2.38 .54 
  
6m 
rCBV 
11 2.16 2.17 1.24 3.74 .77 
  
12m 
rCBV 
11 2.09 1.86 1.37 3.32 .67 
Std: standard; N: number of cases 
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3. Association with transformation  
Relative CBV at study entry significantly predicted transformation (p= 0.05), with an odds 
ration of being a transformer of 2.82 for each SD of rCBV [Standard deviation (SD): 0.62, 
95% Confidence Interval (CI): 0.98 – 7.96]. However it did not survive when histology, age 
and gender were added to the model.  
Relative CBV at 6 and 12 months were not able to predict transformation (p values= 0.14 and 
0.27, respectively), neither did the changes of rCBV between study entry and 6 months 
(p=0.48) nor the rCBV changes between study entry and 12 months (p = 0.22).  
 
4.  Time to transformation analysis   
 
a) Using variable at study entry 
a.1) When astrocytomas and oligodendroglial tumours were analyzed together 
We found that rCBV at study entry was a predictor of time to transformation. The risk of 
becoming a progressive during the study was 1.57 higher per each additional SD of rCBV at 
study entry (p value = 0.026, SD: 0.62, 95% CI: 1.05 – 2.33). These results were independent 
of the other covariates in the model: histology, age and gender. Table 4.5.  
 
a.2) When only astrocytomas were analysed 
Relative CBV at study entry was a predictor of time to transformation. The risk of becoming 
a progressive during the study was 2.09 higher per each additional SD of rCBV at study entry 
(p value = 0.01, SD: 0.52, 95% CI: 1.13 – 3.88). These results were independent of age and 
gender. Table 4.6. 
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a.3)When only oligodendrogliomas and oligoastrocytomas were analysed 
Relative CBV at study entry was not a predictor of time to transformation (p=0.33). 
 
b) Using variable at 6 months  
b.1) When astrocytomas and oligodendroglial tumours were analyzed together 
Relative CBV at 6 months follow up predicted time to transformation. The risk of becoming a 
progressive during the study was 1.62 higher per each additional SD of rCBV at 6 months 
follow-up (p value = 0.028, SD: 0.78, 95% CI: 1.05 – 2.50). However it did not survive when 
other variables were considerate in the model. Table 4.5. 
Changes of rCBV between study entry and 6 months did not predict time to transformation 
(p=0.5). 
 
b.2) When only astrocytomas were analysed 
Neither rCBV at 6 months follow up or changes of rCBV between study entry and 6 months 
predicted time to transformation (p=0.23 and p =0.94, respectively). 
 
b.3) When only oligodendrogliomas and oligoastrocytomas were analysed 
Relative CBV at 6 months follow up did not predict time to transformation (p=0.07). 
Changes of rCBV between study entry and 6 months did predict time to transformation. The 
risk of becoming a progressive during the study was 2.65 higher per each additional SD of 
changes of rCBV within 6 months (p value = 0.02, SD: 0.44, 95% CI: 1.14 – 6.14). However 
it did not survive when age was considerate in the model. Table 4.7.  
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c) Using variables at 12 months  
c.1) When astrocytomas and oligodendroglial tumours were analyzed together 
Relative CBV at 12 months follow up predicted time to transformation. The risk of becoming 
a progressive during the study was 1.51 higher per each additional SD of rCBV at 12 months 
follow-up (p value = 0.03, SD: 1.29, 95% CI: 1.02 – 2.22). However it did not survive when 
other variables were considerate in the model. Table 4.5. 
Changes of rCBV between study entry and 12 months did not predict time to transformation 
(p=0.3). 
 
c.2) When only astrocytomas were analysed 
Relative CBV at 12 months did not predict time to transformation (p=0.37) 
Changes of rCBV between study entry and 12 months did not predict time to transformation 
(p=0.49). 
 
c.3) When only oligodendrogliomas and oligoastrocytomas were analysed 
Relative CBV at 12 months follow up predicted time to transformation. The risk of becoming 
a progressive during the study was 2.08 higher per each additional SD of rCBV at 12 months 
follow-up (p value = 0.04, SD: 1.71, 95% CI: 1.00 – 4.11). However it did not survive when 
other variables were considerate in the model. Table 4.7. 
Changes of rCBV between study entry and 12 months did predict time to transformation. The 
risk of becoming a progressive during the study was 2.06 higher per each additional SD of 
changes of rCBV within 12 months (p value = 0.04, SD: 1.14, 95% CI: 1.03 – 4.13). 
However it did not survive when other variables were added in the model. Table 4.7. 
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Table 4.5. Odds ratio, standard deviation, confidence interval and p values of predictors of 
time to transformation at each time point. All tumour subtypes included 
PREDICTOR  ODDS RATIO STANDARD  
DEVIATION 
CONFIDENCE  
INTERVAL  
P VALUE 
rCBV  
at SE 
1.57 0.62 1.05 – 2.33 0.026 
rCBV  
at 6months*  
1.62 0.78 1.05 – 2.50 0.028 
rCBV  
at 12 months* 
1.51 1.29 1.02 – 2.22 0.03 
SE: study entry. * Results did not survive when other variables were added in the model.  
 
Table 4.6. Odds ratio, standard deviation, confidence interval and p values of the only 
predictor of time to transformation  for patients with low-grade astrocytomas.  
PREDICTOR ODDS RATIO STANDARD  
DEVIATION 
CONFIDENCE  
INTERVAL  
P VALUE 
rCBV at SE 2.09 0.52 1.13 – 3.88 0.01 
SE: study entry. 
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Table 4.7. Odds ratio, standard deviation, confidence interval and p values of the predictors 
of time to transformation for patients with low-grade oligodendrogliomas and 
oligoastrocytomas.  
PREDICTOR  ODDS RATIO STANDARD  
DEVIATION 
CONFIDENCE  
INTERVAL  
P VALUE 
Changes of rCBV  
between SE and  
6 months*  
2.65 0.44 1.14 – 6.14 0.02 
rCBV  
at 12 months* 
2.08 1.71 1.00 – 4.11 0.04 
Changes of rCBV  
between SE  
and 12 months * 
2.06 1.14 1.03-4.13 0.04 
SE: study entry. * Results did not survive when other variables were added in the model. 
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Kaplan Meier curve for the strongest predictor 
When all tumour subtypes were included rCBV at study entry showed to be the strongest 
predictor of time to transformation among other time points. It was then  entered in the 
analysis with the ROC curve.  The analysis showed that the rCBV value at study entry 
associated with the highest specificity was 1.84. This cut off was based on high specificity. 
At 90% specificity on the ROC curve, we get three thresholds (1.84, 1.91 and 1.94), but 1.84 
was chosen because a similar number was previously used in the literature (Law et al., 
2006a).  
When the entire cohort was analysed using this value as a threshold, we found a borderline 
significance difference in time to transformation between patients with rCBV smaller than 
1.84 and those with rCBV equal or above this cut-off (p = 0.06) (Figure 4.2.A). Median time 
to transformation was 2.63 years (95% CI: 1.22 – 4.03) for patients with rCBV at study entry 
less than 1.84, compared with 1.58 years (95% CI: .99 – 2.16) for patients with rCBV greater 
than or equal to 1.84. 
When only astrocytomas were included in the analysis we found a significant difference in 
time to transformation between patients with rCBV smaller than 1.84 and those with rCBV 
equal or above this cut-off (p = 0.03) (Figure 4.2.B). Median time to transformation was 2.63 
years (95% CI: 1.44 – 3.81) for patients with rCBV at study entry less than 1.84, compared 
with 0.99 years (95% CI: 0.07 – 1.91) for patients with rCBV greater than or equal to 1.84. 
When only oligodendrogliomas were analysed there was no significant difference in the time 
to transformation between groups with low and high rCBV (p=0.8). 
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.   Figure 4.2 A. 
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Figure 4.2.C. 
 
Figure 4.2: A) Analysis using entire cohort. Kaplan-Meier survival curve for time to 
transformation within groups with low (<1.84) and high (≥1.84) rCBV. Patients with low-
grade gliomas with low rCBV had a median time to progression of 2.63 years. Patients with 
low-grade gliomas with high rCBV had a median time to progression of 1.58 years. 
B) Analysis using subgroup of astrocytomas. Kaplan-Meier survival curve for time to 
transformation within groups with low (<1.84) and high (≥1.84) rCBV. Patients with low-
grade astrocytomas with low rCBV had a median time to progression of 2.63 years. Patients 
with low-grade gliomas with high rCBV had a median time to progression of 0.99 years. 
C) Analysis using subgroup of oligoastrocytomas and oligodendrogliomas. There was no 
significant difference in the time to transformation between groups with low (<1.84) and high 
(≥1.84) rCBV.  
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4.4 Discussion  
 
Perfusion MRI in gliomas has mostly been used to predict the histological grade (Cha et al., 
2005; Law et al., 2003; Sugahara et al., 1998) and more recently tumour genotype (Jenkinson 
et al., 2006). Law et al (Law et al., 2006a) used baseline rCBV measurement in patients with 
low-grade gliomas, who underwent aggressive treatment, to obtain prognostic information 
about survival and tumour progression.  
In this chapter we used serial perfusion MR imaging over a one year period in a cohort of 
patients with conservatively treated gliomas to assess whether serial rCBV measurements and 
its changes between time points can predict outcome. 
We found significant differences in rCBV between time points. This could be explained by 
the fact that values of rCBV correlate well with vascular endothelial growth factor (VEGF) 
(Maia et al., 2005). The expression of VGEF is promoted by nutrient-deficient states, such as 
tissue hypoxia or hypoglycemia, that occur as tumour cells in rapidly growing pathologic 
tissues expand beyond the limits of diffusion of nutrients from the native capillaries (Shweiki 
et al., 1992). This hypothesis is corroborated by a previous study of longitudinal rCBV 
measurements in a smaller cohort of patients with low-grade glioma that showed a dramatic 
rCBV increase closer to the point of transformation to a high-grade tumour (Danchaivijitr et 
al., 2008).  
In our cohort, rCBV at study entry, 6 and 12 months follow up was not only able to 
differentiate tumours with oligodendroglial elements and those with pure astrocytomas but 
also between oligodendrogliomas, astrocytomas and oligoastrocytomas. This is in keeping 
with the literature where maximum tumour rCBV measurements derived from DSC MR 
imaging were significantly higher in low-grade oligodendrogliomas than in astrocytomas 
(Cha et al., 2005). In addition we demonstrated significantly higher rCBV values in 
oligoastrocytomas compared to pure astrocytomas. The findings of our cohort and available 
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literature suggest that rCBV can be used to distinguish low-grade gliomas subtypes. 
However, no previous publications have studied the association of rCBV with tumour 
subtype at different time points. Interestingly, in our study the significance is higher at study 
entry than at other time points. This could be due to the overall raise in rCBV over time, 
which we found in all subtypes, as the tumour grows and angiogenesis increases. Histological 
classification and the influence of longitudinal rCBV changes on the ability to predict low-
grade gliomas subtypes would have to be clarified in a bigger cohort. 
Law et al (Law et al., 2006a) have shown that rCBV was also able to differentiate patients 
that had an adverse event (transformation or death) from those who did not. In that study 
patients that transformed or died had a higher rCBV. Even though we used a different 
definition for transformation, we showed a borderline difference in the study entry rCBV 
values between patients that presented an adverse event from those who did not.  
Finally we have showed that rCBV at study entry significantly predicted time to 
transformation, independent of histology, age and gender. At time points 6 and 12 months 
rCBV is still predictive, but loses its significance when compared to the other variables in the 
model. When only astrocytomas were analyzed rCBV at study entry was the only predictor of 
time to transformation. Interestingly, changes of rCBV between study entry and 6 and study 
entry and 12 months did not predict transformation when all tumour subtypes were included. 
However it did predict transformation when only oligodendroglial tumours were analyzed. 
This subgroup analysis suggests that values at study entry are most useful in astrocytic 
tumours, whereas changes in rCBV over a short period of time may be more helpful in 
tumours with oligodendroglial elements, which have generally a wider range of rCBV values.  
In a previous study it has been shown that rCBV was a significant predictor of adverse 
outcome (transformation or death) (Law et al., 2006b) and in a different publication the same 
author showed that low rCBV values were associated with longer time to progression (Law et 
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al., 2006a). None of the previous publications has tested if rCBV measurements at different 
time points were also able to predict time to transformation. The same author used an rCBV 
threshold of 1.75 to compare the group with high rCBV and the group with low rCBV in 
terms of time to progression/death (Law et al., 2006a). Lesions with rCBVs that were more 
than 1.75 had a median time to progression/death of 245 days, whereas lesions with rCBVs 
less than 1.75 had a median time to progression/death of 4620 days. In our cohort there was a 
significant difference in time to transformation between patients with rCBV smaller and 
greater than 1.84. Median progression time was 1.58 years for patients with rCBV greater 
than or equal to 1.84 compared with 2.63 years for patients with rCBV at study entry less 
than 1.84.  When only astrocytomas where analysed we also found a significant difference in 
time to transformation between patients with rCBV smaller and greater than 1.84. Median 
progression time was 0.99 years for patients with rCBV greater than or equal to 1.84 
compared with 2.63 years for patients with rCBV at study entry less than 1.84.  When only 
oligodendroglial elements were analysed, there was not a significant difference between these 
two groups. This in keeping with our previous results, as rCBV at study entry did not predict 
time to transformation in this subgroup. It is important to note that on our analysis we used 
transformation as end point whereas Law et all used transformation/death as end point. This 
could already explain differences in time to transformation and time to transformation/death 
between the groups. The former group demonstrated a shorter time to progression/death in 
patients with high rCBV when compared with our study. This could also be explained by the 
fact that we used different definitions of time to transformation. Law et al (Law et al., 2006a) 
used decline in neurologic status or Karnofsky score or increase in tumour size by more than 
25% at MR imaging.  When relying on clinical signs one can assume that transformation is 
detected at a later stage, as changes in imaging appearance precede clinical deterioration. 
Focal contrast-enhancement has proved to be a more reliable indicator of malignancy in 
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gliomas than border definition, mass effect, necrosis and haemorrhage (Daumas-Duport et al., 
1997; Mihara et al., 1995; Pierallini et al., 1997). We therefore selected contrast enhancement 
as criterion for the classification of malignant transformation.  
 In our cohort few patients presented decline in neurologic status after being classified as 
transformers. In contrast, our cohort shows a shorter time to progression in patients with low 
rCBV when compared to the former group. This could be explained because the former study 
also included paediatric patients, which have a longer survival time and that low-grade 
gliomas receive aggressive treatment (i.e. surgery, chemotherapy or radiotherapy) prolonging 
their survival, whereas in our cohort we only recruited adults and these patients are 
conservatively treated until a transformation to a higher grade occurs. Moreover on the 
former study the average follow up was 4.2 years, whereas on ours it was 2.9 years. 
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4.5 Conclusion  
 
In this chapter we have shown that rCBV is an important variable when assessing brain 
gliomas. It contributes towards the understanding of the natural history of brain gliomas, and 
helps to differentiate between tumour subtypes and also much needed prognostic information 
on these patients. Relative rCBV can be used to distinguish between patients that had an 
adverse event from those who did not, but more importantly it can be used to predict time to 
transformation, which it is important when planning treatment. It would be very useful to 
assess if these results could be replicated in other institutions, which will be assessed in 
following chapter.   
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Chapter 5 
Relative cerebral blood volume measurements predict malignant transformation in patients 
with low-grade gliomas, in a two-institution setting 
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5.1 Introduction  
 
Low-grade gliomas (LGG) account for approximately 20% of central nervous system glial 
tumours and, in the United States, approximately 1800 new cases of LGG are reported each 
year. As outlined in chapter 4 most of these tumours transform into more aggressive 
phenotypes at some point in their natural history, however this malignant transformation has 
been difficult to predict so far.  
Multiple studies have assessed factors present at diagnosis that may predict tumour behaviour 
(Bauman et al., 1999; Medbery et al., 1988; Pignatti et al., 2002). In a multi-institutional 
study of 401 patients, aged less than 40 years, with epilepsy as the presenting symptom, and 
absence of contrast enhancement on CT, all were associated with improved survival (Bauman 
et al., 1999).  
Histopathology remains currently the standard reference for determining the glioma biology. 
Primary brain tumours are classified according to their predominant cell type and graded 
based upon the presence or absence of standard pathologic features, such as necrosis, mitotic 
figures, nuclear atypia, and endothelial cell proliferation.  Low-grade astrocytomas have 
increased cellularity and atypia; but no mitoses, endothelial proliferation, or necrosis.  
Although there is an established system of classifying and subclassifying these low-grade 
tumours, the prognostic value of defining subcategories of gliomas is based upon mitotic 
activity, proliferation and/or necrosis is still controversial. One study evaluated the utility of 
the WHO classification of childhood supratentorial astrocytic tumours in 340 children and 
found that the presence or absence of endothelial proliferation, necrosis, and mitosis but not 
other histologic features was inadequate to classify these neoplasms into prognostically 
homogenous groups (Gilles et al., 2000). 
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Central nervous system histopathology is limited by sampling error, in which case the most 
aggressive portion of the tumour may be missed, by inter- and intraobserver variability 
(Coons et al., 1997; Prayson et al., 2000) and by the dynamic nature of gliomas, whereby 
tumours can de-differentiate into more aggressive phenotypes (Jackson et al., 2001). In the 
later study it was shown a discrepancy between the diagnosis made from small biopsy 
samples and the diagnosis from resected specimens. It would be greatly beneficial to clinical 
teams to have an additional method of predicting the behaviour of gliomas which can 
overcome some of these limitations of histopathology and is also reproducible and reliable.  
Measurement of rCBV has been shown to predict time to transformation in our cohort 
(chapter 4) and in another study (Law et al., 2006a). The aim of this chapter is to assess  
whether rCBV measurements can be used to predict patient outcome in a multi-institution 
setting. 
 
5.2 Methods  
 
5.2.1 Patients 
69 consecutive patients with low-grade glioma met the inclusion criteria for this study. 
Inclusion criteria were (i) histologically confirmed brain gliomas, (ii) patients who were 
referred for preoperative assessment for intracranial tumours and (iii) patients who did not 
show evidence of systemic malignancy or immune suppression.   
Patients underwent conventional and perfusion imaging every 6 months at the Institute of 
Neurology (ION) and every 3 months at the New York University Medical Centre 
(NYUMC). At these time points, clinical assessment was also performed.    
The study was approved by the institutional review board and local research ethics committee 
and all patients provided informed consent. 
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5.2.2 MRI protocol  
At the ION, studies were acquired with a 1.5 T system (Signa LX, GE Medical Systems, 
Milwaukee, WI). The following sequences were acquired: pre- and post-contrast 
(0.2mmol/kg) coronal spoiled gradient echo (SPGR) sequence with TR/TE 14.4/6.4 
(repetition time msec/echo time msec), Coronal FLAIR with 8774/161/2192 (repetition 
time msec/echo time msec/inversion msec) and T2-weighted (6000/102).  
 
At the NYUMC, imaging was also performed at 1.5 T (Siemens Vision or Symphony; 
Siemens, Erlangen, Germany).  The following sequences were obtained: pre- and post-
contrast (0.2mmol/kg) transverse T1-weighted spin echo, with 600/14; transverse fluid-
attenuated inversion recovery (FLAIR), with 9000/110/2500; and T2-weighted (3400/119) 
MR imaging. 
 
At both centres, dynamic susceptibility-weighted perfusion contrast-enhanced MR images 
were acquired with a gradient-echo echo-planar imaging sequence during the first pass of a 
standard-dose (0.1 mmol/kg) bolus at a rate of 5ml/sec, except for the 5 patients in the 0–16 
year age group, in whom the injection rate was reduced to 3 ml/sec. The contrast used was 
gadoterate meglumine (Dotarem ®) at the ION and gadopentetate dimeglumine (Magnevist; 
Berlex Laboratories, Wayne, NJ) at NYUMC. Six to 10 sections were positioned to cover the 
tumour based on T2-weighted and FLAIR images. At the ION the imaging parameters were: 
1200/40; field of view, 260 x 260 mm; section thickness, 5 mm, contiguous sections; matrix, 
128 x 92; flip angle, 90°. For the NYUMC, imaging parameters were as follows: 1000/54; 
field of view, 230 x 230 mm; section thickness, 5 mm; matrix, 128 x 128; in-plane voxel size, 
1.8 x 1.8 mm; intersection gap, flip angle, 30°.  
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  Contrast-enhanced T1-weighted MR imaging was also performed at both centres after the 
acquisition of dynamic susceptibility-weighted perfusion contrast-enhanced imaging data.  
 
5.2.3 MRI analysis 
 
1) Relative cerebral blood volume measurements 
The procedure used to calculate relative cerebral blood volume (rCBV) from the dynamic 
susceptibility-weighted perfusion contrast-enhanced MR imaging data was based on standard 
algorithms that have been previously described (Rosen et al., 1991; Rosen et al., 1990). A 
summary of the analysis was published elsewhere (Law et al., 2006a).  
At the ION data processing was performed off-line using Advantage Workstation commercial 
processing software (Functool, General Electric Medical Systems).  At the NYUMC, it was 
performed at a workstation (Unix; The Open Group, San Francisco, Calif) with programs 
developed in house in the C and Interactive Data Language programming languages. In each 
case colour overlay maps of rCBV were produced. To improve the signal-to-noise ratio the 
rCBV measurements used in this study were calculated from ROIs of 15-20 pixels placed in 
regions of highest rCBV on colour overlay maps. At least four separate ROI measurements 
were made, and the maximum rCBV value of these was recorded. This method had been 
shown to provide the highest intra- and interobserver reproducibility of rCBV measurements 
(Wetzel et al., 2002).  Large peri- or intratumoural vessels were avoided when placing the 
ROIs,  as they can be an important confounding factor (Brasil Caseiras et al., 2008).  
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5.2.4 Statistical Analysis 
Analysis was performed in Stata 9 (Stata Corporation, College Station, TX USA) and p<0.05 
was considered to be significant.  
At the last individual follow-up visit patients were classified into four categories: 1) 
Complete response: MR image with no visible tumour and no new neurologic deficit; 2) 
Stable: no change in the neurologic examination or Karnofsky score, a change in tumour size 
of less than 25% at MR imaging; 3) Progressive: was defined as a decline in neurologic status 
or Karnofsky score, an increase in tumour size of more than 25% 4) Death. This classification 
was based in part on the method described by Levin et al (Levin et al., 2003). 
The mean, standard deviation, and median of the rCBV measurements were obtained for 
patients in each clinical-radiological response category.  
 
1. Differences between clinical-radiological outcome groups 
The Mann-Whitney test was used to determine whether there was a significant difference in 
the median of rCBV values between patients that presented a complete response and the ones 
that remained stable. The same analysis was repeated between progressive patients who died.  
 
2. Differences between groups with adverse and non adverse event  
The Mann-Whitney test was used to determine whether there was a significant difference in 
the median of rCBV values between two independent groups.  The grouping variable was the 
presence of adverse event (progressive disease or death) and non adverse event (complete 
response and stable).   
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3. Association of rCBV with adverse event 
To investigate if rCBV at study entry was associated with adverse event, a logistic regression 
analysis was performed.  Firstly, rCBV was modelled individually. Then it was modelled 
together with histology, age and gender. Centre was also added in to the model to assess if 
the results were significantly independent of the institution (i.e. ION or NYUMC). The 
dependable variable was adverse or non adverse event. The covariate was rCBV at study 
entry.  
 
4. Association of rCBV with time to progression 
Kaplan-Meier survival curves and log-rank test were used to characterize and compare the 
group with high (≥ 1.75) and low rCBV (< 1.75) in terms of time to progression.  This 
threshold value had previously been found to give the optimal sensitivity and specificity for 
differentiating low-grade from high-grade gliomas (Law et al., 2003). Time to progression 
was defined as the time from the study entry or initial surgical diagnosis until progression 
was reached. Data for those patients with complete response and stable disease at the time of 
most recent follow-up were appropriately censored. Kaplan Meier survival curves and log-
rank test were then applied to compare the time to transformation in the two groups of 
patients defined by the cut-off.  Differences between the two groups defined were tested 
using the log-rank test. 
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5.3 Results  
Patients 
Sixty-nine patients (23 female and 46 male patients; median age, 40 years; range, 4-80 years) 
were studied for a median total length of 396 days (range from 63 to 2009). Five patients 
were in the 0 – 16 years age group. The pathologic diagnoses were: 34 low-grade 
astrocytomas, 20 low-grade oligodendrogliomas, 9 low-grade mixed oligo-astrocytomas, 1 
ganglioglioma, and 5 with indeterminate histology. Thirty-five patients were followed up at 
the Department of Radiology, NYUMC, whereas 34 were followed up at the ION. 
Four out of 69 patients (5.7%) were defined as complete response, 32 (46.3%) as stable while 
13 (18.8%) were progressive during the follow-up and 17 (24.6%) died. In 3 cases the clinical 
outcome was not known because the patients dropped out of the study and went abroad.  
These patients were excluded from the analysis because of lack of clinical information. 
Thirty-four out of 69 patients were classified as stable or progressive using only the clinical 
criteria whereas the remaining used both radiological and clinical, as described previously.   
At the ION the low-grade gliomas were treated conservatively until there was clinical or 
radiological evidence of disease progression. Following this, 22 patients received treatment 
(surgery: 10; radiotherapy: 14 and chemotherapy: 8 patients).  At the NYUMC cohort 29 
patients received treatment during the study, which included surgery in 27 patients, 
radiotherapy in 20 and chemotherapy in 19 patients.  
The median, mean, and standard deviation for study entry rCBV in each of the four clinical 
response categories are represented in Table 5.1.   
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Table 5.1.  Mean and median relative CBVs for patients with pathologically proven low-
grade glioma in each clinical response category.  
Outcome Mean rCBV ± SD Median rCBV 
Complete Response (n=4) 1.41 ± 0.13 1.44 
Stable (n=32) 1.75 ± 0.91 1.53 
No Adverse Event (n=36) 1.71 ± 0.86 1.49 
Progressive (n=13) 3.21 ± 1.81 3.09 
Death (n=17) 2.06 ± 1.06 1.79 
Adverse Event (n=30) 2.56 ± 1.52 2.38 
N=number of subjects. SD: standard deviation 
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1. Differences between clinical-radiological outcome groups 
Thirty-six patients demonstrated no adverse event, whereas 30 patients had an adverse event. 
There was no significant difference between the median rCBV of patients with complete 
response (n=4) and those with stable disease (n=32) (Figures 5.1 and 5.2). However, a 
significant difference was found between those with progressive disease (n=13) and those 
who died of disease (n=17) (p value = 0.03).  
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Figure 5.1. 26-year-old male with pathology proven low-grade astrocytoma with a low 
baseline rCBV (1.24), which remained stable.  
Top Row : A, Axial FLAIR image; B, Axial T2*-weighted image shows increased signal 
within the middle frontal gyrus on the right side. C, Contrast-enhanced axial T1-weighted 
image demonstrates no appreciable enhancement compatible with an imaging and pathologic 
diagnosis of LGG. D, Gradient-echo axial DSC MRI image with rCBV colour overlay map, 
shows a lesion with low initial perfusion with an rCBV of 1.24 more in keeping with a LGG. 
Bottom Row: E, Axial FLAIR image at 376 days follow up. F, Axial T2-weighted image 
shows a stable appearance to the right frontal LGG. G, Contrast-enhanced axial T1-weighted 
image demonstrates no change in the appearance of the glioma with no enhancement to 
suggest malignant transformation. 
 
 
 
A)          B)                C)    D) 
 
 
 
 
 
 
 
 
 
E)        F)                G) 
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Figure 5.2: 32-year-old male with pathology proven right frontal low-grade astrocytoma, 
which remained stable. Coronal FLAIR image (A) and Axial T2-weighted image (B) shows 
increased signal in the right frontal lobe. C) Contrast-enhanced coronal T1-weighted image 
demonstrates no appreciable enhancement compatible with an imaging and pathologic 
diagnosis of LGG. D) Gradient-echo axial DSC MRI image with rCBV colour overlay map, 
shows areas of highest perfusion within the tumour. rCBV at study entry was 1.61. 
 
 
 
C)         D) 
 
A) B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
C)           D)  
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2. Differences between groups with adverse and non adverse event  
There is a significant difference in the median rCBV values between patients that had an 
adverse event from those who did not (p=0.01), the latter having lower rCBV values than the 
former. 
 
3. Association of rCBV with adverse event 
Relative CBV at study entry was significantly associated with an adverse event, 
independently from age, gender or centre (p = 0.0134). The odds ratio of detecting an adverse 
event was 2.19 (standard deviation: 1.24; 95% confidence interval: 1.15 – 4.16) for each per 
standard deviation of rCBV at study entry. (Figure 5.3). 
 134
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: 28-year-old female with pathology proven left frontal low-grade 
oligodendroglioma, which presented an adverse event. Coronal FLAIR image (A) and Axial 
T2-weighted image (B) shows increased signal in the left frontal lobe. C) Contrast-enhanced 
coronal T1-weighted image demonstrates enhancement. D) rCBV map shows areas of highest 
perfusion within the tumour. rCBV at study entry was 2.81. 
 
 
 
 
 
A) B) 
 
 
 
 
 
 
 
 
 
 
 
 
    C)           D)  
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4. Association of rCBV with time to progression 
Thirty-six patients showed a baseline rCBV < 1.75, compared to 30 with a baseline rCBV ≥ 
1.75. Relative CBV was significantly negatively associated with time to progression or death 
(p=0.0059, 0.0057 for numeric and binary representations, respectively). The median time to 
progression among subjects with rCBV > 1.75 was 365 days, 95% confidence interval: 355 to 
742 days, while the median time to progression among subjects with rCBV < 1.75 could not 
be estimated (since more than 50% of these subjects were progression-free at time of last 
observation). However, there is 95% confidence that the median in this cohort was at least 
889 days (Figure 5.4).   
 
 
 
 
 
 
 
 
 
 
Figure 5.4.  Kaplan-Meier survival curves for time to progression within groups with low (< 
1.75) and high (rCBV > 1.75) at both institutions. Patients with low-grade glioma with low 
rCBV at baseline had a probable median time to progression of 889 days, whereas the median 
time to progression among subjects with high rCBV was 365 days. 
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5.4 Discussion  
 
In this multi-institution study we demonstrated a significant difference in mean rCBV values 
between patients with progressive disease and those who died, and were also able to detect 
the presence of an adverse event using rCBV at study entry, independently from histology, 
gender, age or centre.   
Previous studies have also shown that patients with an adverse event had a significantly 
higher rCBV than did patients who did not have an adverse event and also that rCBV was 
significantly negative associated with survival (Law et al., 2006a). Aronen et al (Aronen et 
al., 1994) demonstrated that patients with brain gliomas with rCBV> 1.5 were more likely to 
develop into high-grade gliomas. Similarly, Tzika et al (Tzika et al., 2004) demonstrated that 
blood volume measurements could be used to distinguish between progressive and stable 
tumours in paediatric patients. These higher rCBV values in certain patients with low-grade 
glioma could be explained by the fact that they might already have high-grade components at 
the time of the histopathologic assessment or that rCBV is possibly higher in patients that are 
undergoing malignant transformation.  Whatever the reason, it appears that LGGs with higher 
rCBV are more likely to behave as high-grade tumours, whereas LGGs with lower rCBV 
values are more likely to behave as a true low-grade glioma (Law et al., 2006a). 
An important finding was the significant negative association of rCBV with time to 
progression.  Patients with low-grade gliomas and high rCBV (> 1.75) had a median time to 
progression of 365 days, whereas in patients with low rCBV (< 1.75) there was a 95% 
confidence that the median time was 889 days. Although caution should be taken when 
adopting a threshold value, this cut-off has previously been found to give the optimal 
sensitivity and specificity for differentiating low- from high-grade gliomas at a single 
institution (Law et al., 2003).  
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Other studies have shown similar results. Lev et al (Lev et al., 2004) demonstrated a mean 
survival time of 24 months for patients with rCBV > 1.75 and Law et al (Law et al., 2006a) 
presented a median survival time of 8 months for patients with rCBV > 1.75. However 
Leighton et al (Leighton et al., 1997) reviewed the outcome of patients with pathologically 
confirmed low-grade glioma and showed a median time of survival for patients with low-
grade glioma of 10.5 years and a median progression-free survival of 4.9 years. This 
difference could be explained by the fact that changes in rCBV might be an indicator of 
imminent or occurring malignant transformation; alternatively it may reflect histological 
sampling error and inter- or intrapathologist variability leading to erroneous classification of 
a high-grade glioma as a low-grade tumour. 
One limitation of a multi centre study is the use of different MR systems in each centre. 
However in this study the MR sequences used in both centres for Dynamic Susceptibility-
weighted Perfusion Contrast-enhanced MR Imaging were highly comparable, with both using 
a gradient echo technique. This is an important consideration as DSC MRI using spin-echo 
techniques generally yields lower rCBV values (Sugahara et al., 2001).  
Another important factor for successful multi-centre study is to standardize the post 
processing methods. In this study it was agreed to use the highest rCBV value of several ROI 
placements, as previously described by Wetzel (Wetzel et al., 2002) and to exclude large 
intra- and peri-tumoural vessels from the rCBV measurements (Brasil Caseiras et al., 2008).  
There were differences in the definition criterion for malignant transformation. The current 
clinical practice at the ION is to use contrast enhancement as a criteria for transformation, 
which has been shown to be a more reliable indicator of malignancy in gliomas (Daumas-
Duport et al., 1997; Mihara et al., 1995; Pierallini et al., 1997). At the NYUMC 
transformation is defined by clinical criteria and by an increase in tumour volume, but 
enhancement is not included as a radiological sign. For the purpose of this multi-centre study, 
 138
it was decided by senior ION and NYUMC members to adopt the NYUMC criteria of 
transformation. One of the reasons to exclude enhancement as an additional criterion for 
malignant transformation was that many of the NYUMC patients had extensive surgery at an 
early stage and that post operative enhancement could have been a confounding factor.   
In this chapter the time to event analysis uses transformation or death as the end point, 
whereas in other chapters, where only data from the ION was used, time to transformation 
and death are analyzed separately. Despite using different criteria and end points, the results 
were independent from the centres and chapters 4 and 5 show consistent results regarding the 
potential of rCBV for differentiating patients that had an adverse from those who did not. 
Both chapters showed that rCBV at study entry is able to predict time to transformation or 
time to transformation/death.  
Finally, there were differences in the treatment protocols between the two cohorts. At the 
NYUMC patients received either stereotactic resection or biopsy, with or without radiation 
therapy, as initial treatment. At the ION patients had a biopsy at study entry but only received 
aggressive treatment after radiological evidence of malignant transformation was diagnosed, 
using the enhancement criteria described above. This means that all 34 ION patients were 
initially treatment-free. Nevertheless, in both groups the majority patients received treatment 
at some point during the study (22 patients received treatment during the study at the ION 
and 29 patients at the NYUMC). Despite these differences in the timing of more aggressive 
forms of treatment, rCBV proved to be a significant and independent predictor of patient 
outcome in the combined data of the two centres.    
The current standard reference for glioma grading is histopathology diagnosis. As mentioned 
before, there are several limitations, including sampling error. The triage, treatment and 
survival statistics of low-grade gliomas based of histopathology alone therefore, remain a 
challenge. Measurement of  rCBV are less subject to sampling error as the entire tumour can 
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be assessed by DSC MRI using appropriate slice positioning. Measurements of rCBV 
correlate with regional tumour vascularity and expression of vascular endothelial growth 
factor (VGEF) (Maia et al., 2005), which represent important biological aspects that 
influence tumour behaviour.  
The fact that rCBV measurements correlated well with time to progression or death, and that 
these findings can be replicated between institutions, provides an argument for the more 
widespread use of rCBV measurements as an adjunct to the pathology. We anticipate that 
DSC MRI will play an increasing role in assessing the risk of transformation in individual 
patients and may contribute towards a tailored approach to low-grade glioma management 
and treatment strategies.  
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5.5 Conclusion  
 
Despite differences in the MRI equipment and therapeutic approaches between the two 
institutions rCBV at study entry has proved to be a useful predictor for time to transformation 
or death. This demonstrates the potential use for rCBV measurements in larger scale multi-
centre study for low-grade gliomas. Such studies would also allow looking at the outcome of 
astrocytomas and oligodendrogliomas separately. In the following chapter, we will test the 
predictive value of rCBV measurements against other imaging parameters such as ADC and 
tumour volume and growth.  
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Chapter 6 
Tumour volume and tumour growth predict outcome in patients with brain gliomas better 
than rCBV and ADC 
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6.1 Introduction  
 
As described in chapter 4 the management of LGG remains controversial. However in a more 
recent study (Smith et al., 2008) it has been demonstrated that patients with low-grade glioma 
who underwent a at least 90%  extent of resection had 5- and 8-year overall survival rates of 
97% and 91% respectively. Similarly Claus et al (Claus et al., 2005) demonstrated that the 5-
year age-adjusted and histologic-adjusted death rate for patients who underwent surgical 
resection using intraoperative MRI guidance was 17.6%. A randomised multi-centre trial 
[European Organization for Research and Treatment of Cancer (EORTC)] showed that early 
radiotherapy in adult LGG increases the median transformation-free survival but not the 
overall survival when compared with delayed radiotherapy (van den Bent et al., 2005).   
In view of the morbidity associated with surgery and radiotherapy some centres, including 
ours, adopt a “watch and wait” policy in neurologically intact patients, especially with 
tumours in eloquent locations, and instigate aggressive therapy at the time of malignant 
transformation. 
Magnetic Resonance Imaging (MRI) plays an important role in diagnosing malignant 
transformation in gliomas and imaging changes often precede clinical deterioration.  On 
conventional MR imaging the development of areas of focal contrast-enhancement is the 
most commonly used sign of transformation to a high-grade glioma, in clinical practice 
(Mihara et al., 1995; Pierallini et al., 1997).  
Conventional MRI images are also used to quantify changes in tumour size, which are most 
commonly obtained using linear measurements (Levin et al., 2003). A serial study of 
untreated oligodendrogliomas and mixed gliomas measured mean tumour diameters and 
demonstrated a constant growth of these tumours during the “premalignant” phase 
(Mandonnet et al., 2003). The same group subsequently analysed growth rates of WHO 
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Grade II gliomas, based on tumour diameter, and found an inverse relationship between 
individual growth rates and survival (Pallud et al., 2006).  
As discussed in previous chapters, perfusion-weighted MR imaging has been successfully 
used in the investigation of brain tumours. Measurements of rCBV correlate well with 
histological measurements of tumour vascularity (Sugahara et al., 1999b) and presence of 
vascular endothelial growth factor (VGEF) (Maia et al., 2005). DSC perfusion MRI 
significantly improves on the specificity and sensitivity of conventional MRI in 
differentiating between high and low-grade gliomas (Law et al., 2003) . In chapters 4 and 5 it 
was demonstrated rCBV is a useful predictor of time to transformation.  
Apparent diffusion coefficient (ADC) measurements have been used for glioma grading, with 
conflicting results (Cha, 2006). Two recent studies found pre-treatment ADC measurement in 
high-grade astrocytomas (WHO grade III and IV) a useful predictor of patient survival 
(Higano et al., 2006; Murakami et al., 2007). 
The purpose of this chapter was to identify radiological markers of tumour behaviour and to 
determine the best predictor of patient outcome. We surmise that this will help to stratify the 
risk of early transformation and contribute to clinical decision making, particularly with 
respect to timing of aggressive forms of therapy. Therefore we compared the tumour volume, 
rCBV and ADC in a cohort of patients with conservatively-treated low-grade glioma as 
predictors of the overall patient outcome and the time to malignant transformation and to 
death.  
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6.2 Methods  
 
6.2.1 Patients 
All patients were recruited sequentially from the neuro-oncology clinic of the National 
Hospital for Neurology and Neurosurgery, in London. The inclusion criteria were: (i) 
histologically confirmed WHO grade II gliomas (Kleihues P, 2000); (ii) no previous 
treatment except biopsy (surgery, radiotherapy or chemotherapy) and (iii) age ≥ 18 years. 
Patients underwent conventional, perfusion and diffusion imaging at study entry, 6 months 
and 12 months. For the remainder of the study patients were clinically assessed and MR 
imaging was performed at six monthly intervals. The study was approved by the local 
research ethics committee and all patients provided informed consent. 
 
6.2.2 MRI protocol 
All MR data were acquired with a clinical 1.5 T system (Signa LX, GE Medical Systems, 
Milwaukee, WI, USA). The following images were acquired: 
1) 3D Coronal Spoiled gradient echo (SPGR) sequence, as mentioned on chapter 4. 
 
2) 2D Coronal oblique FSE fluid-attenuated inversion recovery (FLAIR)  as mentioned 
on chapter 4.  
 
3) Axial Dynamic susceptibility-weighted perfusion sequence, as mentioned on chapter 4. 
4) Axial Diffusion-weighted images (DWI) using a single shot spin-echo EPI sequence 
[TE=99.5ms; TR=10000ms; 128 x 96 matrix; 26cm x 26cm FOV; slice thickness 5mm, 
contiguous sections]. Images were acquired at b=0 and b=1000 s mm2 by applying the 
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diffusion gradients along three orthogonal axes to produce three diffusion-weighted 
images which were then co-added. 
 
6.2.3 MRI analysis 
1) The analyses of the pre- and post-contrast SPGR images was previously described on 
chapter 4.  
 
2)  FLAIR images were analysed, blinded to clinical details, on a Sun workstation 
(Sunblade 150, Sun Microsystems, Mountain View, CA, USA) using DispImage v. 
4.9 software (Plummer, 1992). Semi-automated contouring technique was used to 
calculate tumour volume at each time point  (Figure 6.1). The intra-rate correlation 
calculated on two separate measurements in 57 tumours was 0.98 (95% CI: 0.97-
0.98).    
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Figure 6.1: A) Coronal FLAIR image showing right frontal lobe low-grade 
astrocytoma. B) Semi automatic contour on DispImage for determination of tumour 
volume. The volume at entry study of this patient was 93.30ml. 
 
A) 
A)                                      B)) 
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3) The analyses of dynamic susceptibility-weighted perfusion images was previously 
described on chapter 4. Figure 6.2.  
 
 
 
      
  
 
 
 
 
 
 
 
Figure 6.2:  A) T2-weighted image showing a left frontal low-grade oligodendroglioma. B) 
T2*-weighed image during the maximum arterial and venous contrast concentration. C) 
rCBV map demonstrating the position of a ROI yielding maximum CBVs within the tumour 
(red ROI). Note that intra-tumoural vessels (yellow ROI) were avoided while placing the 
ROI. The mean CBV from contra-lateral white mater was used to normalize the data. 
 
 
 
 
 
 
A)     B)    C)  
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4) ADC maps were generated using commercial image processing software (Functool 1.9, 
General Electric Medical Systems). The tumour was contoured on each slice of the b=0 
images and the saved regions were applied to the ADC map using DispImage v 4.9 
software. Whole tumour ADC histograms were generated using DispImage following 
transfer of ADC maps onto a Sun Workstation. This method has been described in detail 
elsewhere (Tozer et al., 2007) (Figure 6.3). The histograms were normalized for the total 
number of tumour pixels and bin width. The following histogram parameters were 
extracted and used in the statistical analysis: peak height (PH), peak location (PL), mean 
value, 10th, 25th, 50th, 75th and 90th centile points. 
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Figure 6.3. Determination of ADC histogram. Each tumour was contoured on all slices of the 
b=0 sequence (A) and copied into the ADC map (B). A whole tumour ADC histogram was 
generated from all pixels within the tumour contours (C).  
 
 
 
 
A)) B)) 
C) 
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6.2.4 Statistical analysis 
Analysis was performed in Stata 9 (Stata Corporation, College Station, TX USA) and p<0.05 
was considered to be significant.  
 
1.  Changes in MRI parameters over time 
The Friedman test was used to analyze the distribution of tumour volume, rCBV and ADC 
values at study entry, 6 months and 12 months, and to assess whether there were significant 
changes of the mean values between these three time points. 
 
2. Ordinal logistic regression analysis 
 To investigate which MRI measure (tumour volume, rCBV and ADC histogram parameters) 
at study entry, 6 months and 12 months was associated with patient outcome, independently 
from the others, and from histology, age and gender, an ordinal logistic multiple regression 
analysis was repeated for each time point.  Firstly, predictors were modelled individually. 
Secondly, the significant radiological predictors were modelled together to determine the set 
of independent significant predictors.   
 The dependent variable was “patient outcome”, which was classified at the last individual 
available follow-up visit into three categories of roughly equal sizes: 1) Stable: patients 
without radiological evidence of malignant transformation. These patients’ MRI studies 
showed either no enhancement or stable enhancement of the tumour since study entry (n=12), 
2) Progressive: patients with radiological evidence of malignant transformation showing one 
or more new areas of contrast enhancement or increase in previously stable enhancement 
(n=13), and 3) Death (n=11). As mentioned in previous chapters, contrast enhancement was 
used as criterion for transformation. 
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This ordinal variable was used as outcome in a multiple ordinal logistic regression in order to 
determine independent predictors.  The following covariates were used: tumour volume, 
tumour rCBV, diffusion histograms parameters, histology, age and gender. Tumour histology 
was first divided into two groups: the first group included tumours with oligodendroglial 
elements (oligodendrogliomas and oligoastrocytomas; total number=14); the second group 
included pure astrocytomas (total number=22). Then tumour histology was also divided into 
three different groups: i) oligodendrogliomas (n=8), ii) astrocytomas (n=22) and iii) 
oligoastrocytomas (n=6). 
The same analysis was then repeated to determine whether changes in tumour volume, rCBV 
and ADC histogram parameters between 6 months and study entry and 12 months and study 
entry were associated with patient outcome, independently from the other MRI changes, 
histology, age and gender.  
 
3.  Time to event analysis 
To complete the analysis of the association between MRI parameters and outcome, we also 
investigated the best independent predictors of time to transformation and time to death. This 
analysis allowed us to check whether the predictors found to be significant in the ordinal 
logistic regression analysis were also predictors of time to transformation and time to death. 
 
(i)Predictors of time to transformation   
A Cox regression was used with time measured as years from study entry to transformation. 
Stable patients were censored at last follow-up. The covariates at each time point were: 
histology (including 2 tumour subtypes and 3 tumour subtypes), gender, age, tumour volume, 
rCBV, ADC parameters and changes of these parameters in 6 and 12 months. Firstly, 
predictors were modelled individually. Secondly, the significant radiological predictors were 
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modelled together to determine the set of independent significant predictors. Treatment was 
not added to the model because patients were treatment free until transformation was reached. 
We performed a subgroup analysis using only astrocytic tumours which represent 61% of our 
cohort and of tumours with oligodendroglial elements, which represent 39% of our cohort.  
 
(ii)Predictors of time to death  
The same analyses were repeated with time as years from study entry to death. However on 
this analysis, the presence of treatment was added to the model as a covariate. Patients alive 
at the time of latest follow-up were censored at that time. 
 
Kaplan Meier curves for the strongest predictors 
Kaplan Meier curves were produced for the strongest predictors of time to transformation and 
of time to death. 
A receiver operating characteristic (ROC) analysis was applied to assess which variable cut-
off at study entry and at short-term changes had the highest accuracy of prediction to allow 
the differentiation between patients who progressed to high-grade gliomas and those who did 
not, and between alive and dead patients, respectively. Kaplan Meier survival curves and log-
rank test were then applied to compare the time to transformation and time to death in the two 
groups of patients defined by the cut-off.  Differences between the two groups defined were 
tested using the log-rank test. 
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6.3 Results  
Patients 
Demographic data are shown in Table 6.1.  
Thirty-six patients (mean age: 42; SD 12.8 ; 24 males and 12 females) with histology proven 
WHO grade II gliomas (22 astrocytomas, 8 oligodendrogliomas and 6 oligoastrocytomas) 
were studied for a median total follow-up length of 2.9 years (range 0.4 – 5.5). All 36 patients 
had MRI studies at 6 months after study entry, while 4 (11%) patients failed to attend the 12 
months scan (1 patient died, 1 patient went abroad for treatment, and 2 patients clinically 
progressed and dropped out).  
Twelve out of 36 patients (33.3%) remained stable during the follow-up, while 13 patients 
(36.1%) progressed and 11 (30.5%) died. All deaths were related to tumour progression. The 
median length of follow-up was 2.4 years for the stable (range: 0.4 – 5.3 years) and 2.0 years 
for the progressive group of patients (range: 0.5 – 5.5 years). Patients who died were 
radiologically followed-up for a median of 2.0 years (range: 0.5 – 3 years), but were 
clinically studied for longer (median 3.9 years; range 1- 4.8). 
Patients did not receive any treatment until malignant transformation. Twenty-two out of 36 
patients (61%) received treatment during the study, which included surgery in 9 patients, 
radiotherapy in 16 patients and chemotherapy in 8 cases. The median time from study entry 
to treatment was 2.4 years (range: 0.6 – 5.5). Only 2 patients received treatment within the 
first year of the study, but both cases were treatment-free at study entry and 6 months; no 
further MRI data were available after the first 6 months in these 2 cases.  
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Table 6.1. Demographic data and MRI parameters at study entry for all patients 
PATIENT 
ID,  
AGE AND 
GENDER 
 
HISTOL
OGY 
VOLU
ME IN 
ML 
AT SE 
RCBV 
 
MEDIAN 
ADC  
 
OUTCOME YEARS OF 
FOLLOW 
UP 
1 30 F O 45.6 2.02 1131.5 P 3.1 
2 51 M A 93.3 2.46 1215.5 P 0.5 
3 30 M A 83.4 2.00 1480.5 D 4.8 
4 57 M O 132.2 1.94 1205.5 P 3.6 
5 25 M OA 84.6 1.28 1149.5 D 1.6 
6 37 M A 77.1 0.99 1289.5 P 5.6 
7 30 M A 77.0 0.94 1749.5 S 0.4 
8 56 M O 72.0 2.53 1229.5 P 4.6 
9 38 M A 73.9 na 1400.5 P 3.8 
10 48 M OA 83.1 1.26 1450.5 D 3.0 
11 56 M A 84.2 1.04 1169.5 D 2.9 
12 42 F OA 101.0 1.91 1342.5 D 3.8 
13 58 M A 169.3 2.24 1122.5 D 1.0 
14 29 F A 59.0 2.38 1674.5 D 4.2 
15 41 M A 136.9 1.04 2013.5 D 2.2 
16 34 M A 58.7 1.56 1643.5 P 1.9 
17 47 F A 75.0 1.09 1466.5 D 4.8 
18 28 F O 24.4 2.81 978.5 P 1.2 
19 35 M A 64.8 0.91 1669.5 D 4.2 
20 65 F OA 92.3 1.28 1649.5 P 4.0 
21 30 M A 106.7 1.91 1504.5 D 4.1 
22 24 M O 44.6 1.59 1241.5 P 2.0 
23 52 M A 40.4 1.37 1151.5 P 1.7 
24 53 F O 94.9 1.84 1569.5 P 2.1 
25 37 F OA 105.4 na 1369.5 S 1.5 
26 63 F O 38.9 1.47 1322.5 S 3.5 
27 36 M O 71.6 3.51 1291.5 P 1.3 
28 60 F A 47.5 1.14 1307.5 S 1.1 
29 38 M A 79.1 0.80 1491.5 S 2.0 
30 69 M OA 37.4 1.94 1169.5 S 5.3 
31 29 F A 43.8 1.18 1767.5 S 2.7 
32 32 M A 20.1 1.61 1256.5 S 2.4 
33 57 F A 72.3 1.49 1275.5 S 4.3 
34 32 M A 42.9 1.42 1843.5 S 1.6 
35 39 M A 30.8 1.79 1364.5 S 0.6 
36 29 M A 66.0 0.70 1724.5 S 3.7 
 
SE: study entry, F: female, M: male, A: astrocytoma, O: oligodendroglioma, OA: 
oligoastrocytoma, na: not available due to technical problems, S: stable, P: progressive, D: 
death. 
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1.  Changes in MRI parameters over time 
There were significant changes in the mean values of the tumour volume between study 
entry, 6 months and 12 months and in the mean values of rCBV between these time points 
(all p values were < 0.001). There were significant changes in the mean values of tumour 
growth in 6 and 12 months (p<0.001) and in the mean values of changes in rCBV in 6 and 12 
months (p=0.034). The whole tumour ADC histogram parameters did not show any 
significant change between time points.  
The mean values and standard deviation of tumour volume, rCBV and ADC for each time 
point and the change of these parameters within the first 6 and 12 months after study entry 
are given in Table 6.2. The mean values and standard deviation of ADC parameters for each 
time point and the change of these parameters within the first 6 and 12 months after study 
entry are given in Table 6.3. 
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Table 6.2. Mean, standard deviation, median and range values of tumour volume, maximum 
rCBV and ADC 50th centile, at each time point and of tumour growth within the first 6 and 12 
months.  
  
TIME POINT / 
CHANGES 
BETWEEN TIME 
POINTS  
VOLUME  
MEAN 
(SD) 
VOLUME  
MEDIAN 
(RANGE) 
MAX. 
RCBV 
MEAN 
(SD) 
MAX. 
RCBV  
MEDIAN 
(RANGE) 
ADC 50TH  
(X10-6 MM2S-1 ) 
CENTILE 
MEAN (SD) 
ADC 50TH  
(X10-6 MM2S-1 ) 
CENTILE  
MEDIAN 
(RANGE) 
At study entry (SE) 73.06 (32.32) 73.11  
(20.11-
169.31) 
1.63 (0.63) 1.53  
(0.70-3.51) 
1407.86  
(240.72) 
1353.50  
(978.50- 
2013.50) 
At 6 months 81.82 (35.15) 81.94  
(21.96-
186.77) 
2.22 (0.79) 2.03  
(1.24-4.62) 
1387.44  
(258.94) 
1319.50  
(978.50-2013.50) 
 Change between 
SE and 6 months  
8.76  
(7.06) 
9.18  
(-11.88-
23.36) 
0.47 (0.36) 0.34  
(0.08-1.81) 
-5.47  
(74.67) 
00  
(-246-180) 
Change between SE 
and 12 months  
2.69  
(3.68) 
1.62  
(00-19.56) 
0.89 (0.87) 0.71  
(-0.94 -4.39) 
-0.84 
(80.63) 
00 
 (-221 – 257) 
SE: study entry; SD: standard deviation; N: number of subjects 
Mean and median values of volume are given in millilitres.  
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Table 6.3: Mean, standard deviation, median and range values of ADC parameters, at each 
time point. 
ADC parameters at  
each time point 
Mean Std Deviation Median Minimum Maximum 
Study entry  ph .04 .01 .04 .02 .06 
Study entry  pl 1327.31 429.09 1334.00 9.50 2113.50 
Study entry  mean* 1401.77 212.03 1370.47 1016.45 1885.33 
Study entry  10th centile* 1051.19 170.32 1045.00 689.50 1384.50 
Study entry  25th centile* 1216.75 202.53 1171.50 818.50 1673.50 
Study entry  50th centile* 1407.86 240.72 1353.50 978.50 2013.50 
Study entry  75th centile* 1593.97 256.58 1596.00 1158.50 2173.50 
Study entry  90th centile* 1798.42 308.75 1778.00 1318.50 2629.50 
6 months ph .04 .01 .04 .02 .06 
6 months pl 1388.62 305.53 1297.50 995.50 2113.50 
6 months mean* 1394.73 227.63 1355.17 1016.45 1882.92 
6 months 10th centile* 1052.15 180.70 1003.00 718.50 1529.50 
6 months 25th  centile* 1209.79 223.78 1154.00 818.50 1749.50 
6 months 50th  centile* 1387.44 258.94 1319.50 978.50 2013.50 
6 months 75th centile* 1561.56 262.99 1536.00 1155.50 2173.50 
6 months 90th centile* 1740.38 265.40 1733.50 1318.50 2333.50 
12 months ph .036 .010 .035 .021 .068 
12 months pl 1384.88 307.63 1366.00 879.50 2113.50 
12 months mean* 1411.08 214.87 1391.89 1003.23 1885.33 
12 months 10th centile* 1051.75 155.81 1035.00 709.50 1386.50 
12 months 25th centile* 1214.88 205.09 1174.00 829.50 1673.50 
12 months 50th centile* 1402.38 249.55 1344.00 989.50 2013.50 
12 months 75th centile* 1589.25 256.77 1571.00 1149.50 2173.50 
12 months 90th centile* 1778.63 252.19 1782.50 1309.50 2333.50 
* (x10-6 mm2s-1 ); ph: peak height; pl: peak location. 
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2. Ordinal logistic regression analysis 
Tumour volume obtained at study entry, 6 months and 12 months significantly predicted 
patient outcome, better than, and independently from, rCBV, ADC values, histology, age and 
gender. In particular, the tumour volume showed a significant association with patient 
outcome, with an odds ratio of being in a more severe outcome category of 3.15 [Standard 
Deviation (SD): 32.32, 95% Confidence Interval (CI) (1.42 - 7.00), p=0.005] at study entry 
(Figure 5.4), 4.47 (SD: 35.14, 95% CI: 1.77 – 11.24, p=0.001) at six months and 9.48 (SD: 
58.39, 95% CI: 2.00 – 44.93, p=0.005) at twelve months, for each additional SD of tumour 
volume (Table 6.4). In contrast, neither rCBV nor ADC values were associated with outcome 
at any time point (all p values > 0.05). 
 
 
Figure 6.4. Graph showing association between tumour volume at study entry (ml) and 
outcome categories.  
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Changes in tumour volume between study entry and 6 months and between study entry and 
12 months were also significantly associated with patient outcome, independent of short-term 
changes in rCBV and, of histology, age and gender (p=0.001 and p=0.004 respectively).  The 
odds ratio of being in a more severe outcome category was 6.68 (SD: 7.05, 95% CI: 2.26-
19.70) for each SD of tumour growth over the first 6 months and 93.24 (SD: 3.67, 95% CI: 
4.13-2101.05) for each SD of tumour growth over the first 12 months. Table 6.4. 
Changes in rCBV and ADC during the first 6 and 12 months did not predict patient outcome. 
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Table 6.4: Results from the ordinal logistic regression showing the ability of tumour volume 
in predicting patients’ outcome at each time point.  
TIME POINT ODDS RATIO SD  CONFIDENCE 
INTERVAL 
P VALUE 
Volume at 
Study Entry 
 
3.15 32.32 1.42-7.00 0.005 
Volume at 6 
Months 
 
4.47 35.14 1.77-11.24 0.001 
Volume at 12 
Months 
 
9.48 58.39 2.00 – 44.93 0.005 
Changes in 
volume within 
6 months 
 
6.68 7.05 2.26 – 19.70 0.001 
Changes in 
volume within 
12 months 
 
93.24 3.67 4.13 – 2101.05 0.004 
SD: standard deviation; n: number of subjects 
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3. Time to event analysis  
(i) Predictors of time to transformation   
 
a) Using variables at study entry 
 
We found that tumour volume and rCBV were both independent predictors of time to 
transformation at study entry. The risk of transforming during follow up was 2.39 higher per 
each additional SD of tumour volume at study entry (95% CI 1.36-4.20, p = 0.002, SD: 
32.32) and 1.66 higher per each additional SD of rCBV at study entry (95% CI: 1.06 – 2.61, p 
= 0.02, SD: 0.62). (Table 6.5).These results were independent of the other covariates in the 
model: histology, gender, and age.  ADC histogram measures were not significantly 
associated with time to transformation.  
Even when only astrocytomas were analyzed, tumour volume and rCBV at study entry were 
still predictors of time to transformation.  The risk of transforming during follow up was 2.48 
higher per additional SD of tumour volume at study entry (95% CI 1.29 – 4.76, p= 0.006, SD: 
33.64) and 4.23 higher per each additional SD of rCBV at study entry (95% CI 1.67-10.72, p 
= 0.002, SD: 0.52).  
 
b) Using variables at 6 months  
 
A Cox regression analysis using all parameters available at 6 months (including the study 
entry data) showed that changes in tumour volume over 6 months was the only independent 
predictor of time to transformation: the risk of transforming during the study was 3.25 higher 
per each additional SD of tumour growth within 6 months (95% CI: 1.62 – 6.49, p value = 
0.001, SD: 7.05).  
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c) Using variables at 12 months 
Tumour volume and changes in tumour volume between study entry and 12 months were the 
only independent predictors of time to transformation at 12 months follow up. The risk of 
transforming during the study was 4.73 higher per each additional SD of tumour volume at 12 
months (95% CI: 1.15 – 19.41, p = 0.03, SD: 58.39). The risk of transforming during the 
study was 2.48 higher per each additional SD of tumour growth within 12 months (95% CI: 
1.35 – 4.56, p = 0.03, SD: 3.67) (Table 6.5.). 
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Table 6.5: Predictors of time to transformation  
TIME 
POINT 
PREDICTOR ODDS 
RATIO 
SD CI P VALUE 
Study entry 
 
Tumour 
volume 
 
2.39 32.32 1.36 - 4.20 0.002 
 
rCBV 1.66 0.62 1.06 - 2.61 0.02 
6 months* 
 
Changes in 
tumour 
volume 
 
3.25 7.05 1.62 - 6.49 0.01 
12 months 
 
Tumour 
volume  
 
4.73 58.39 1.15 - 
19.41 
0.03 
 
Changes in 
tumour 
volume 
2.48 3.67 1.35 - 4.56 
 
0.03 
SD: standard deviation; CI: confidence interval; n: number of subjects when all parameters 
are present. 
* A Cox regression analysis using all parameters available at 6 months (including the study 
entry data) showed that changes in tumour volume within 6 months, rather than volume and 
rCBV at study entry, was the only independent predictor of time to transformation.  
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(ii) Predictors of time to death  
a) Using variables at study entry  
Tumour volume at study entry was the only independent predictor of time to death: the risk of 
dying at any time of the study was 5.54 per each additional SD of tumour volume at study 
entry (95% CI: 1.79 – 17.12, p value = 0.003, SD: 32.32) (Table 6.6).  
 
b) Using variables at 6 months 
Tumour volume and changes in tumour volume between study entry and 6 months were the 
only independent predictors of time to death at 6 months follow up. The risk of dying at any 
time of the study was 4.31 per each additional SD of tumour volume at study entry (95% CI: 
1.75 – 10.59), p value = 0.001, SD: 32.32. The risk of dying at any time of the study was 2.46 
per each additional SD of tumour growth within 6 months (95% CI: 1.11 – 5.42, p value = 
0.02, SD: 7.05) (Table 6.6).  
 
c) Using variables at 12 months 
Tumour volume and changes in tumour volume between study entry and 12 months were the 
only independent predictors of time to death at 12 months follow up. The risk of dying at any 
time of the study was 6.81 per each additional SD of tumour volume at study entry (95% CI: 
2.08 – 22.62, p value = 0.002, SD: 58.39). The risk of dying at any time of the study was 2.80 
per each additional SD of tumour growth within 12 months (95% CI: 1.35-5.79, p value = 
0.005, SD: 3.67) (Table 6.6).  
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Table 6.6. Predictors of time to death 
TIME 
POINT 
PREDICTOR ODDS 
RATIO 
SD CI P VALUE 
Study Entry 
 
Tumour 
volume  
4.31 32.32 1.75 – 
10.59 
0.001 
6 months 
 
Tumour 
volume 
4.51 35.14 1.81 – 
11.22 
0.002 
 
Changes in 
tumour 
volume 
2.46 7.05 1.11-5.42 0.02 
12 months 
 
Tumour 
volume 
6.81 58.39 2.08 – 
22.62 
0.002 
 
Changes in 
tumour 
volume  
2.80 3.67 1.35 – 5.79 0.005 
SD: standard deviation; CI: confidence interval. 
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Kaplan Meier curves for the strongest predictors  
As tumour growth within the first 6 months and tumour volume at study entry were the best 
independent predictors of time to transformation and to death, respectively, they were entered 
in the analysis with the ROC curve.  
 
a) Strongest predictor of time to transformation 
This analysis showed that the tumour growth in the first 6 months was associated with the 
highest accuracy of prediction of time to transformation was 6.21ml (sensitivity: 83.3%; 
specificity: 83.3%; correctly classified: 83.3%). Using this value as a cut-off, we found a 
significant difference in time to transformation between patients with tumour growth smaller 
than 6.21ml and those with tumour volume equal or above this cut-off  (p = 0.003) (Figure 
6.5). Mean time to transformation was 3.91 years (95% CI: 2.81 - 5.02) for patients with 
tumour growth within 6 months less than 6.21 ml compared with 1.84 years (95% CI: 1.44 – 
2.24) for patients with tumour growth greater than or equal to 6.21 ml.    
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Figure 6.5.  Graph showing comparison of time to progression between groups with small (< 
6.21 ml) and large (≥ 6.21 ml) tumour growth within 6 months. Patients with small tumour 
growth mean time to progression of 3.91 years (blue curve), whereas patients with large 
tumour growth had a mean time to progression of 1.84 years (red curve). Note that, after 3 
years of follow up, all patients with large tumour growth had transformed, whereas almost 
60% of patients with small tumour growth did not transform.  
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b) Strongest predictor of time to death 
A ROC curve showed that the tumour volume associated with the highest accuracy of 
prediction of time to death was 83.14ml (sensitivity: 66.67%; specificity: 79.17%; correctly 
classified: 75%). Using this value as a cut-off, we found a significant difference in survival 
between patients with tumour volume smaller than 83.14ml and those with tumour volume 
equal or above this cut-off (p = 0.0016) (Figure 6.6). Mean survival time was 5 years (95% 
CI: 4.52 – 5.48) for patients with tumour volumes at study entry less than 83.14 ml compared 
with 3.27 years (95% CI: 2.49 - 4.05) for patients with tumour volumes greater than or equal 
to 83.14 ml.    
 
 
 
 
 
 
 
 
 
 
 169
 
 
 
Figure 6.6.  Graph showing comparison of survival between groups with small (< 83.14ml) 
and large (≥ 83.14ml) tumour volumes at study entry. Patients with small tumour volumes 
had a median survival time of 5 years (blue curve), whereas patients with large tumour 
volume had a median survival time of 3.27 years (red curve). Note that, after almost 5 years 
of follow up, all patients with large tumour volume would probably be dead, whereas more 
than 40% of patients with small tumour volume would still be alive.  
 
 
 
 
 
 
 
0.00 
0.25 
0.50 
0.75 
1.00 
0 2 4 6 Analysis time (years)   
Volume < 83.14ml Volume ≥ 83.14ml 
 
Su
rv
iva
l r
at
e 
 170
6.4 Discussion  
 
We have, for the first time, investigated tumour volume, rCBV and ADC histogram 
parameters in a longitudinal study of patients with conservatively treated low-grade gliomas 
to determine the best MRI predictor of outcome. Previous retrospective studies have explored 
tumour volume (Mariani et al., 2004) and tumour growth (Dempsey et al., 2005; Mariani et 
al., 2004; Pallud et al., 2006) as individual predictors of outcome and/or survival in patients 
with brain gliomas. However, the novelty of the work presented in this chapter lies in the 
prospective comparison of several MR variables as predictors of outcome. 
We found that tumour volume at study entry and tumour growth were the strongest predictors 
of patient outcome, which was assessed using 3 categories (i.e. stable, progression and death). 
These parameters remained significant when adjusting for the other MRI variables, histology, 
age, gender and treatment. Furthermore when performing a time to event analysis, tumour 
growth in the first 6 months was the best independent predictor of time to transformation and 
tumour volume at study entry was the only independent predictor of time to death.  
Our results are broadly in keeping with previous studies investigating tumour volume and 
growth in low-grade gliomas. Mariani (Mariani et al., 2004) performed a retrospective study 
of tumour volume over a 9-year-period and found preoperative tumour volume to be the 
strongest predictor of overall survival. They also stated that tumour volume was the only 
predictor of malignant transformation. However oligodendrogliomas were not included and 
all patients were treated surgically prior to malignant transformation.   
Pallud et al (Pallud et al., 2006) found an inverse correlation between individual growth rates 
of low-grade gliomas and patient survival. Tumours with a median growth rate below 
8mm/year had a much better prognosis than tumours with higher growth rates. This was a 
large study (143 patients), but was retrospective,  spanning a 12-year-period, with a large 
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variation of the time interval between successive MRI studies ranging from 3 to 219.3 
months (mean, 33.4 months). In contrast to our study, there was a heavy bias towards 
oligodendrogliomas, which accounted for two thirds of tumours studied, perhaps reflecting 
local differences in neuropathological criteria. In addition, measurements were based on 
maximum tumour diameters in three planes rather than true volumetric calculations and some 
patients had surgery before malignant transformation.  
Based on our time to death analysis, it can be predicted that patients with a tumour volume 
exceeding 83.14 ml are likely to die within 5 years of presentation. Other studies have shown 
different survival rates. The EORTC work (van den Bent et al., 2005) demonstrated that the 
median survival for patients who received radiotherapy was 7.4 years compared with 7.2 
years for patients who did not receive radiotherapy. It has also been demonstrated that WHO 
grade II gliomas survival rate is around 8 years (Claus et al., 2005; Smith et al., 2008). This 
could be attributed to the fact that in all these studies patients with low grade glioma received 
surgery after the diagnosis, whereas our patients were treatment free until they progressed to 
high-grade gliomas and only 25% underwent surgery during the study.  
Despite the fact that oligodendrogliomas have been reported to have a better outcome than 
astrocytomas (van den Bent, 2007), we found that predictors of patient outcome, time to 
transformation and time to death were independent  not only from gender and age but also 
from histology. One explanation could be the small number of pure oligodendrogliomas in 
our cohort (n=8). However if all tumours with oligodendroglial elements are taken into 
account, they represent 39% of the cohort, making the group roughly balanced with pure 
astrocytomas.  
As mentioned in previous chapters, parameters derived from physiological MR imaging such 
as rCBV and ADC measurements provide additional information about tumour behaviour, 
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which goes beyond morphological aspects.  In this chapter, we found that rCBV at study 
entry is a predictor of time to transformation, but not as strong as tumour growth.  
In our cohort 9 of 12 stable patients had low-grade astrocytomas. As it is known that this 
tumour subtype have lower rCBV compared to oligodendrogliomas (Cha et al., 2005), 
another Cox regression was used to investigate if rCBV remained a predictor of time to 
transformation when only astrocytomas were considered. The results confirmed the potential 
of rCBV in predicting time to transformation in the subgroup of purely astrocytic tumours.  
As it was discussed in chapter 4, Law and colleagues (Law et al., 2006a) demonstrated a 
significant negative correlation between rCBV and time to progression in a patient cohort 
which differed from ours in several respects, previously mentioned.  Law et al did, however, 
not compare rCBV with ADC and tumour growth or tumour volume at study entry. Using a 
Cox regression survival model we were able to demonstrate that tumour growth within 6 
months was in fact a stronger predictor for time to progression than rCBV.  In addition, rCBV 
was not a predictor of time to death or of patient outcome in the ordinal logistic multiple 
regression analysis, when compared with other variables.  In an earlier study Lev et al 
showed a correlation of normalized CBV with survival, but this became non-significant once 
age and histological grade were added to the model (Lev et al., 2004). 
A recent MR perfusion study of low-grade gliomas, showed that rCBV increases significantly 
within 12 months prior to malignant transformation (Danchaivijitr et al., 2008), which might 
reflect neo-angiogenesis in low-grade gliomas that are evolving to a higher grade. It may be 
that the predictive value of rCBV measurements for patient outcome increases nearer the time 
of transformation, but this will have to be confirmed with further studies.  
With respect to the ADC measurements, we did not find significant changes over time within 
one year. This is not entirely unexpected as measurement of ADC has been, on the whole, 
less promising than rCBV measurements (Cha, 2006) in differentiating between low- and 
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high-grade tumours. ADC parameters at each time point and changes in ADC between study 
entry and 6 months and between study entry and 12 months did not predict patient outcome 
neither time to transformation or time to death. This is in contrast with a retrospective study 
(Higano et al., 2006). The author showed that pre-operative ADC measurements were able to 
predict the prognosis of anaplastic astrocytomas and glioblastomas.  Tumours with a 
minimum ADC above 0.90 x 10-3 mm2 sec-1 had a better prognosis than those with lower 
ADC values. However, this study used manual ROI placement over solid tumour portions to 
identify the lowest intratumoural ADC values, which is more operator-dependent than the 
histogram analysis we used. It also included paediatric patients, who usually have a better 
prognosis (Chandler et al., 1993; Devaux BC, 1993; Salcman et al., 1994). 
 
Methodological considerations 
In this thesis, tumour volume was calculated, rather than using linear measurements of 
tumour size. Dempsey et al  (Dempsey et al., 2005) had compared volumetric, bidimensional, 
and unidimensional measurements of tumour size in 70 patients with recurrent malignant 
glioma and showed that only the volumetric measurement was found to be predictive of 
survival in patients with brain gliomas. Additionally other studies which compared linear 
tumour measurements with clinical outcome yielded inconsistent findings (Chow et al., 2000; 
Reeves and Marks, 1979; Wood et al., 1988).  
 
We have chosen to outline the tumour volume on FLAIR images, as these have  been 
demonstrated to be more sensitive to subtle glioma tumour volume change than T2 WI 
(Connor et al., 2004). For our volume measurements, we used the coronal FLAIR images 
with an interslice gap of 1.5mm. Although this might lead to less precise measurements than 
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contiguous slices, the tumour volumes were big enough to consider the possible effect of 
partial volume to be negligible.  
In accordance with our current clinical practise, we used contrast enhancement as 
radiological criterion for transformation since it had proved to be a more reliable indicator of 
malignancy in gliomas than border definition, mass effect, necrosis and haemorrhage 
(Daumas-Duport et al., 1997; Mihara et al., 1995; Pierallini et al., 1997). 
 
Our patient cohort included a mixture of low-grade astrocytomas, oligoastrocytomas and 
oligodendrogliomas, which is representative of the typical mix of histological subtypes seen 
in neuro-oncological practice. The documented differences in rCBV and ADC values 
between low-grade oligodendrogliomas and low-grade astrocytic tumours may be a 
confounding factor when analyzing the predictive value of these parameters in a mixed 
group. Low-grade oligodendrogliomas tend to have higher rCBV values (Cha et al., 2005) 
and lower ADC values (Tozer et al., 2007) than low-grade astrocytic tumours. However when 
only low-grade astrocytomas were analyzed, we demonstrated that rCBV at study entry 
proved to be a predictor of time to transformation. It may be useful in future to look at the 
predictive value of rCBV and ADC in astrocytomas and oligodendrogliomas separately in a 
larger patient cohort. 
 
Of the statistical methods used, the time to transformation and death analysis are more 
powerful at detecting associations between early predictor variables and outcome than the 
logistic regression. The logistic regression analysis provides information about the likelihood 
of patient status after a fixed time interval: although this is a simpler form of analysis, it can 
be easier to interpret and apply in a clinical setting, when a likely outcome may be more 
important than its timing. Another statistical consideration regards the determination of the 
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thresholds for our time-to-event analyses (time to progression and time-to death).  The 
thresholds of tumour volume and tumour growth were obtained with the ROC analysis and 
were based on the highest accuracy of prediction. However, a confidence interval was not 
available, as is usually the case when working with ROC analysis. Although the cut-off 
acquired was the most successful threshold in our cohort, it is worth cautioning that the exact 
optimal threshold determined from the ROC analysis for our dataset may not be generalized 
to a different population. Whilst we would expect comparable datasets to show similar 
prediction, slightly different cut-off thresholds are likely to be obtained. Further studies are 
required to investigate an optimal binary threshold which may be used in daily clinical 
practice. 
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6.5 Conclusion  
This chapter shows the result of an original prospective study which compares tumour 
volume with other variables presented in previous chapters (rCBV and ADC) in order to find 
the best predictor of outcome in patients with low-grade glioma. After using different 
statistics tests, tumour volume was not only associated with outcome, but also tumour growth 
within 6 months was the best independent predictor of time to transformation and tumour 
volume at study entry was the only independent predictor of time to death. Acquisition and 
calculation of tumour volumes can easily performed with standard MRI equipment. The 
incorporation of tumour volume measurements into the diagnostic work-up of patients with 
brain gliomas may prove a useful adjunct in clinical decision making and could influence the 
timing of aggressive treatment.  
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Conclusions   
 
The aim of this thesis was to apply conventional, perfusion- and diffusion-weighted MR 
imaging in patients with histology proven low-grade gliomas in order to provide further 
insights into the biological behaviour these brain tumours, which could influence their 
clinical management. 
After comprehensive work using the analysis of rCBV, ADC and conventional MRI in a 
unique cohort, I have been able to show how these techniques can contribute to the 
understanding of the natural history of low-grade gliomas.  
Although ADC is able to differentiate oligodendrogliomas from astrocytomas (Tozer et al., 
2007) and is useful in the grading of gliomas (Sugahara et al., 1999a), ADC histogram 
parameters were not able to demonstrate an association with patient outcome or with time 
transformation or death. Further studies with bigger cohorts will be needed to verify the 
utility of ADC as a predictor of outcome. 
However, rCBV proved to be an important tool in the study of gliomas. Relative CBV is not 
only associated with transformation but it is also able to predict time to malignant 
transformation in our centre and also in a multi-centre cohort.  
When ADC, rCBV and tumour growth and volume were compared in order to find the best 
MR predictor of  patient outcome in patients with low-grade glioma, tumour volume and 
tumour growth at different time points were stronger predictors than  rCBV and ADC and 
also independent of age, gender, histology and treatment.  When a time to event analysis was 
used comparing tumour volume, tumour growth, rCBV and ADC, tumour growth proved to 
be the best independent  predictor of time to transformation and tumour volume was the only 
independent predictor of time to death. 
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These original results make an important contribution for the management of patients with 
brain gliomas and provide additional information which may help early decision making in 
clinical practice.  
In the National Hospital for Neurology and Neurosurgery patients with low-grade glioma are 
only treated once malignant transformation is diagnosed. However our survival and time to 
transformation is much shorter than the ones described in the literature.  This work lead 
clinicians in this institution to question whether or not patients with brain glioma that had 
tumours volume at study entry bigger than 83.14ml and / or a tumour growth of 6.21ml in the 
first 6 months should be regarded as high grade tumours. It may be appropriate that these 
patients are managed more aggressively.  
 
 179
Future directions 
 
Previous chapters demonstrated the importance of MRI parameters in understanding the 
natural history and predicting prognosis in patients with brain gliomas. There is scope for 
further work, whereby rCBV and ADC may be used to improve the diagnosis and treatment 
of these patients.  
The acquisition of rCBV using DSC MRI remains somewhat subjective with inter and intra 
observer variability. Young and al (Young et al., 2007) also demonstrated that histogram 
analysis of perfusion MR provides prediction of glioma grade. Law et al (Law et al., 2007) 
showed that rCBV acquired using histogram analysis is as effective as rCBVmax in the 
correlation of glioma grade. The histogram method simplifies the analysis and may allow 
inexperienced operators to obtain reproducible data. It would be interesting to implement this 
method for future acquisitions of rCBV. 
 
There is a need to provide imaging markers for treatment response in patients with brain 
gliomas. Chenevert et al (Chenevert et al., 2000) showed that increased diffusion values 
could be detected in human brain tumours shortly after treatment initiation. Another study has 
demonstrated that regions within the 80% isodose of radiotherapy showed a reduction in 
rCBV over a 3 month period (Price et al., 2007). Perfusion-weighted MRI allows in vivo 
imaging of the overall tumour vascularity and an indirect assessment of tumour angiogenesis, 
which is an essential indicator for tumour classification and determination of biological 
aggressiveness (Cha et al., 2002). Additionally, diffusion-weighted MRI reflects pathologic 
features, such as changes in cellularity (Provenzale et al., 2006), which is present as the 
tumour progresses. In summary rCBV and ADC could be used as potential markers for 
treatment response. Changes in treatments could be made if certain imaging markers have not 
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changed over a period of time. It would be reassuring to know that effective treatment is 
mirrored by significant changes in MRI markers. 
Another important application of these techniques is differentiation of radiation necrosis from 
tumour recurrence in patients with primary and secondary brain tumours.  
Differentiation between tumour recurrence and treatment-related brain injury is often difficult 
with conventional MRI. It is unclear whether a previously reported increase of contrast 
material uptake in patients with irradiated primary and secondary tumours are transient due to 
the radiation itself or is due to tumour progression or necrosis. Diffusion-weighted imaging 
appears helpful because water diffusion is greater in necrotic tumours than in tumour tissues 
in recurrence. It has been demonstrated that there are significant differences in the maximal 
ADC values between radiation necrosis and tumour recurrence (Asao et al., 2005). It has also 
been shown that there is a dose-related reduction in rCBV in normal brain after radiotherapy 
(Price et al., 2007) and that rCBV is able to predict patient outcome and monitor radiation-
induced effects (Fuss et al., 2001; Fuss et al., 2000). However the best marker for 
differentiating radiation necrosis from tumour progression remains unclear. A long 
radiological follow up would be needed as patients with a single brain metastasis have a 
median survival in the range of 10–18 months (Melisko et al., 2008) and that treated low-
grade glioma have 5-year survival rate of 97% (Smith et al., 2008) .  
Finally, the use of diffusion tensor imaging (DTI) would be extremely beneficial to plan 
surgical treatment in these patients. DTI is able to identify subtle white matter disruptions  
(Price et al., 2003) and also delineate margins in glioma (Price et al., 2006). Such techniques 
can improve the delineation of surgery resection and also in planning radiotherapy treatment. 
Ideally this sequence would be used in the neuronavigation system improving the 
respectability of brain tumours. 
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